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The Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is 
a severe debilitating systemic disease of unknown etiology that involves multiple systems 
including the nervous, immune, endocrine, digestive, and skeletal systems, accompanied by 
dysfunction of energy metabolism and cellular ion transport. CFS/ME patients show a 
persistent, unexplained fatigue accompained by a number of secondary symptoms including 
cognitive dysfunctions, unrefreshing sleep, post-exertional malaise.  
Due to the great heterogeneity of CFS/ME populations, to date there are not specific 
biomarkers and diagnostic tests for this pathological condition. Some features of the 
syndrome, such as the “relapsing-remitting” symptoms, the higher prevalence in the women 
and a persistent immune activation, suggest a similarity with autoimmune conditions. 
Subjects with CFS/ME also suffer gastrointestinal symptoms, already described in Irritable 
Bowel Syndrome (IBS), often correlated with a change in the intestinal microbial 
composition. The oral and gut microbiota are the most complex microbial community in 
the human body and it is well known that both are able to display signatures associated with 
pathologies. Changes in the intestinal bacterial composition have been detected in metabolic 
diseases, intestinal disorders, autoimmune conditions, cancer and in several neurological 
disorders, highlighting that there is a strong correlation between dysbiosis and the 
pathological condition and therefore, changes in the composition and function of the 
microbiota could be somehow implicated also in the pathogenesis of CFS/ME. Although 
some studies have reported alterations of intestinal and oral microbiota in CFS/ME, the 
relationship between the bacterial composition and the pathogenesis of this syndrome has 
not yet fully demonstrated.  
For these reasons, the present research aimed to investigate the features of intestinal and 
oral bacteriome in adult patients with CFS/ME in order to assess whether any changes in 
the microbial composition may be somehow involved in the pathogenesis of CFS/ME and 
to determine whether any observed differences could be useful in the future for the 
identification of diagnostic biomarkers. 
To this purpose, in this study 105 volunteers were enrolled: 35 CFS/ME patients, diagnosed 
according to Fukuda’s criteria, were investigated and compared with a population of 
relatives without CFS/ME living with patients and a healthy control group chosen outside 




a metagenomic approach was applied. This approach involved the direct isolation of total 
DNA from fecal and salivary samples followed by the selective amplification of bacterial 
DNA using specific universal primers for the hypervariable regions V3-V4 of the 16S rRNA 
prokaryotic gene. Amplicons were sequenced using NGS high-throughput platform 
(MiSeq-Illumina); bioinformatic and statistical analysis, using dedicated softwares 
(Mothur, R), were applied for comparing, analyzing and interpreting sequencing data.  
Based on the results of intestinal bacterial composition in CFS/ME patients, a pilot study 
was conducted on a subgroup of CFS/ME patients which belonged to a same cluster at 
family level to evaluate whether the metabolic profile of CFS/ME patients differed from 
those of their relatives and external controls. The metabolic analysis was performed on fecal 
samples by an Ultra Performance Liquid Chromatography (UPLC) interfaced with a high-
resolution Q-ToF mass spectrometer (MS).  
The results of the present study showed significant variations in both the intestinal and oral 
bacterial composition between CFS/ME patients, their relatives and external controls, due 
to changes in the relative abundances of several bacterial taxa. Interestingly, the relatives, 
in the most cases, showed intermediate prevalence values.  
Considering the fecal bacterioma, the analysis at taxon level showed a reduction of 
Firmicutes and, on the contrary, a significant increase of Bacteroidetes in CFS/ME patients 
in comparison with the non-CFS/ME groups. 
The reduction of Firmicutes and the increased proportion of Bacteroidetes observed in 
CFS/ME patients and in their relatives was mainly ascribed to members of Clostridiales 
and Bacteroidales, respectively. Within Clostridiales, several families declined, with 
Lachnospiraceae showing the greatest decrease. A significant reduction of genus 
Anaerostipes was observed in CFS/ME patients and in their relatives. In addition, 
Phascolarctobacterium faecium and unclassified Ruminococcus were significantly 
increased only in CFS/ME patients compared to external control group. 
A significant increase in Bacteroidaceae and Barnesiellaceae, particularly Bacteroides and 
Barnesiella genera, was observed both in CFS/ME patients and their relatives. Bacteroides 
vulgatus, unclassified Bacteroides, Bacteroides uniformis, Bacteroides ovatus and 
unclassified Barnesiella resulted significantly more abundant in CFS/ME patients and in 
their relatives. 
The analysis of salivary bacterioma revealed a greater species richness than that observed 
in feces, although few differences between the experimental groups were observed. The 
comparison among CFS/ME patients, their relatives and external controls pointed out major 




increased abundance of Actinobacteria observed in CFS/ME patients and, to a minor extent, 
in their relatives was associated with a higher prevalence of Actinomycetales. Within this 
order a significant increase of Micrococcaceae, particularly Rothia sp., was observed only 
in CFS/ME patients. Two pathogenic species belonging Rothia genus were identified, 
Rothia dentocariosa and Rothia mucilaginosa, although the statistical significance was 
obtained only for Rothia dentocariosa. 
The fecal metabolic profile in a subgroup of CFS/ME patients resulted to be different 
compared to that of their relatives and external controls, although the differences were not 
statistically significant. An overall increase of SCFAs and indole derivatives was observed 
in the CFS/ME cohort in comparison with the non-CFS/ME groups, suggesting an increase 
in the fermentation processes. 
In light of the results obtained, CFS/ME patients showed alterations in the composition of 
both the fecal and salivary microbiota, with more marked differences observed in the gut. 
While confirming the results of previous studies (Fremont et al., 2012; Shukla et al., 2015; 
Giloteaux et al., 2016), these results add new information and support the autoimmune 
hypothesis for CFS/ME condition in that in this study the intestinal microbial profile 
recorded in CFS/ME patients is consistent with that reported for autoimmune conditions, 
such as Chron’s disease (Manichanh et al., 2006), ulcerative colitis (Maukonen et al., 2015) 
and Systemic Lupus Erythematous (Hevia et al., 2014). 
In CFS/ME patients, the decrease in the abundance of several butyrate-producting bacteria 
belonging to Lachnospiraceae may result in the alteration of the integrity of the intestinal 
barrier and in a reduced protective action against gut inflammation. The increase of 
Bacteriodes species, some of which are able to damage the intestinal barrier by means of 
their virulence factors, may compromise the permeability of the intestinal barrier, resulting 
in a “leaky gut”, and promote bacterial translocation in the bloodstream, causing an 
abnormal systemic inflammatory response.  
As oral microbial communities are closely connected with the intestinal microflora and 
influence its composition, the higher prevalence in CFS/ME patients of oral opportunistic 
pathogens (i.e. Rothia dentocariosa) able to cause infections in several body sites, may alter 
the composition of their gut microbiota and dysregulate their immune tolerance. 
The gradual increase or decrease of most bacterial taxa observed in CFS/ME patients and 
in their relatives compared to external controls, suggest the presence of a modified 
microbiome profile also in patients’ relatives, affected by genetic and environmental factors 




The metabolic analysis carried out on a subgroup of the three experimental populations 
allowed to record some differences in the fecal metabolic profiles of CFS/ME patients. 
Although the observed differences were not statistically significant, some data appear very 
interesting and deserve to be deeper investigated. These results, if confirmed by using a 
larger cohort, may lead to a better understanding of the relationship between metabolic 
changes and CFS-related immunological and cognitive dysfunctions.  
In conclusion, this work represents the first microbiological study carried out on an Italian 
population of CFS/ME by applying the NGS techniques and including the relatives of 
CFS/ME patients. To obtain data that are truly representative of the pathological condition 
it will be of crucial importance to analyze a larger cohort of patients and perform 
longitudinal studies using the same workflow.  
Further studies are needed to better understand whether the alteration of the microbiota is a 
cause or a consequence of the onset of CFS/ME and if the alterations of the microbiota are 
related to any of the several secondary symptoms.  
Despite evidences of altered composition of the intestinal and oral microbiota in CFS/ME, 
a specific microbial signature attesting a pathogenic role of the microbiota in CFS/ME has 
not yet been identified. If our results will be confirmed by larger studies, the differences 
detected in the microbial and metabolic profiles of CFS/ME patients may be used as markers 
for a more accurate diagnosis of the syndrome and for the development of specific 
















The thesis work reported here aims to investigate the intestinal and oral bacterioma of adult 
subjects affected by Chronic Fatigue Syndrome (CFS). CFS is a debilitating multi-systemic 
disease that mainly affects young women aged 25 to 40 and is characterized by severe 
debilitating fatigue and a combination of symptoms such as problems in concentration and in 
short-term memory, sleep disorders and musculoskeletal pain. (IoM, 2015) 
The problem of health and economic management of patients affected by this pathology has 
aroused a growing interest by health institutions in different countries. In Italy, this pathological 
condition is poorly known and diagnosed. However, the Italian National Agency for Regional 
Health Services (AGENAS) has developed the first guidelines on CFS that collect the current 
knowledge on both the etiology and pathophysiology of this disease. The lack of biomarkers 
and specific diagnostic tools for this syndrome causes long delays in its diagnosis and 
consequent serious discomforts for patients. Although various causal hypotheses have been 
formulated (infectious, immunological, cognitive, genetic), to date the etiology of CFS is still 
unknown. Subjects with CFS also report gastrointestinal symptoms, already described in 
Irritable Bowel Syndrome (IBS), and often correlated with a change in intestinal microbial 
composition (dysbiosis). Indeed, one of the current hypothesis is that in these subjects occurs 
an alteration of the intestinal microbiota: in particular, the replacement of some bacterial species 
would induce signals able to alter the existing equilibrium (mutualism and tolerance).  
The analysis of the oral and intestinal bacterial communities is motivated by the fact that they 
are the most complex microbial community in the human body and it is well known that both 
are able to display signatures associated with pathologies (Abe et al., 2018; Shengtao et al., 
2019). 
Changes in the biodiversity of microbiota has been observed in several diseases, suggesting a 
strong correlation between dysbiosis and pathological conditions. Therefore, changes in the 
composition and function of the microbiota could be somehow implicated also in the 
pathogenesis of CFS.  Today the use of new culture-independent methodological approaches 
and the availability of last-generation sequencing technologies (NGS) allow to point out the 
wide diversity of microbial communities - and thus the effects of community changes on human 
health - more effectively than in the past decades. In this study, the oral and intestinal bacterial 
composition of patients with CFS was analyzed and compared with that of two healthy control 




Association of CFS patients (AMCFS-onlus), was carried out by applying the NGS analysis of 
prokaryotic 16S rRNA gene amplicons. Bioinformatic and statistical analyses allowed to 
identify the bacterial taxa and detect differences in oral and intestinal microbial communities 
between CFS patients and healthy subjects. 
 
 
1.1 Chronic Fatigue Syndrome / Myalgic Encephalomyelitis 
Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is a severe 
debilitating systemic disease that involves multiple systems, including the nervous (Chen et al., 
2008), immune (Fletcher et al., 2010; Lorusso et al., 2009), endocrine (Cleare, 2003), digestive 
(Lakhan and Kirchgessner, 2010), and skeletal (Jones et al., 2009) systems, and is associated 
to dysfunctions of both energy metabolism and cellular ion transport (Myhill et al., 2009). 
CFS/ME patients show a persistent, unexplained fatigue and a number of secondary symptoms 
including cognitive dysfunctions, unrefreshing sleep, post-exertional malaise, myalgia and joint 
pain, that negatively affect the quality of patients’ life greatly affecting their routinary daily 
activities (IoM, 2015).  
The CFS/ME was described for the first time after two outbreaks that occurred in the mid-1980s 
in Nevada, near Lake Tahoe, and in New York. In those occasions, hundreds of people showed 
symptoms very similar to those caused by flu that lasted for an unusually long time and were 
characterized by unexplained muscle fatigue and cognitive abnormalities (Holmes et al., 1988). 
 
 
1.1.1 Epidemiology of CFS/ME 
The first study on the epidemiology of CFS/ME was carried out by the Center for Disease 
Control and Prevention (CDC) in the late 1980s (Gunn et al., 1993); the CFS/ME prevalence 
was assessed to be 4 – 8,7 ind. per 100,000 (Reyes et al., 1997). Larger studies estimated that 
between 800.000 and 2.5 million people are affected by CFS/ME in the U.S.A., resulting in a 
significant social impact and an annual economic cost of 17-24 billion dollars (Jason et al., 
2006; Jason et al., 2008).  
CFS/ME predominantly affects young adults, with a peak age of onset between 20 and 40 years, 
and is more common in women than in men, with a male/female ratio of 1:4 in some cohorts 
(Reyes et al., 2003; Capelli et al., 2010) Some recent investigations in the U.S.A. and U.K. 
indicate an average prevalence of 1.0% and 1.1% respectively for the two countries (Reyes et 




and prevalence estimates are available only at regional-scale (Capelli et al., 2015). A survey 
conducted between 2001 and 2010 by the Italian National Agency for Regional Health Services 
(AGENAS) assessed that CFS/ME prevalence in Italy should range between 0,1% and 0,2% 
(Lorusso et al., 2014). 
 
1.1.2 Etiological factors of CFS/ME 
The etiology and pathogenetic mechanisms of CFS/ME are currently unknown. However, 
several hypotheses have been proposed since the second half of the 20th century (Fig. 1). 
 
Infectious hypothesis. The infectious hypothesis is the oldest. A disease with the same 
symptomatology of CFS/ME was described in closed populations (convents and hospitals), 
suggesting a possible infectious etiology or the association of the onset of the disease with 
concurrent viral infections (Shelokov et al., 1957; Albrecht et al., 1964). In many CFS/ME 
patients the onset of the disease occurs after an infectious event with flu-like symptoms.  A 
previous Epstein-Barr virus (EBV) infection was found in 11% of subjects with CFS/ME, with 
a high IgG antibody titer, indicating an episode of infectious mononucleosis (Hichie et al., 
2006). This virus, infects more than 90% of the global human population, but in most cases it 
is not diagnosed as it causes only slight flu symptoms. However, not all individuals with 
CFS/ME have a significant antibody titer for EBV and for this reason several studies have been 
carried out to identify other possible viruses as triggers of CFS/ME. 
Several other viruses have been associated with the onset of CFS/ME including the Ross River 
virus (Hichie et al., 2006), human herpesvirus-6 (Ablashi et al., 2000), parvovirus B19 
(Fremont et al., 2009), and human enteroviruses (Chia, 2005). Nonetheless, EBV remains the 
most frequently recorded virus. Studies conducted on murine models investigated the role 
played by EBV proteins expressed during viral replication in the induction of the disease. In 
mice, the stimulation of the immune system through dUTPase induced immuno-modulating 
effects similar to the clinical symptoms observed in subjects with CFS/ME. These effects 
included the lowering of physical activity and body mass index, which were correlated to the 
increasing production of inflammatory cytokines, and increase in IFNγ synthesis and activity 
of Natural Killer cells (Glaser et al., 2005; Glaser et al., 2006). 
Although a specific infective causal agent of the disease has still not been identified, the 
interaction of some infectious agents in a predisposed individual may induce the dysregulation 
of the immune system, causing the ineffective containment of the pathogen, persistence of 





Figure 1. Physiology and Pathophysiology of CFS/ME. Scheme of physiogical mechanisms and risk factors involved in CFS/ME 
pathogenesis. (Carlisle S., & Thompson, J., 2014. Imagine retrieved from https://healthlifemedia.com/healthy/what-is-
chronic-fatigue-syndrome-cfs/) 
 
Immunological hypothesis. This hypothesis is based on the observation that CFS/ME could 
be the consequence of an abnormal behavior of the immune system in response to an infectious 
stimulus. CFS/ME can occur with inflammatory symptoms and is characterized by an 
“abnormal” immune response after physical exertion (Nijs et al., 2014). Several non-specific 
immunological abnormalities have been described in CFS/ME: alterations of cell-mediated 
immunity, with a reduction in the activities of Natural Killer cells a strong increase in pro-
inflammatory cytokines levels (IL-1β, IL-6, TNFα) (Blundell et al., 2015; Horning et al., 2015), 
and a decreased expression of Interferon-γ (IFN-γ) (Carlo-Stella et al., 2006). These data 
support the hypothesis that the activation of inflammatory mechanisms occurs in subjects with 
CFS/ME (Glaser et al., 2005).  
Furthermore, some features of the syndrome, such as “relapsing-remitting” symptoms, the 
higher prevalence in women and persistent immune activation, suggest a similarity with 




circulating immunocomplexes have been detected in some individuals with CFS/ME, 
supporting the hypothesis that CFS/ME could be an autoimmune disease (Skowera et al., 2002). 
This hypothesis is supported by the results obtained by a clinical study which showed that a 
monoclonal antibody (Rituximab), that acts by depleting B cells (which, in their turn, produce 
autoantibodies), allowed a significant reduction in fatigue scores and a general improvement in 
health conditions of CFS/ME patients after 8 months of treatment (Fluge et al., 2011). 
 
Neuro-endocrinological hypothesis. The etiology of CFS/ME can be explained by the 
Microbiota-Gut-Brain Axis, which represents the physiological network between the 
microbiota, the Central Nervous System (CNS), the autonomic and enteric nervous system and 
the hypothalamic-pituitary-adrenal (HPA) axis (Demitrack et al., 1991). 
In healthy subjects the physical and emotional stress activates the HPA axis, stimulating the 
synthesis and secretion of hormones, particularly cortisol. Preliminary studies in subjects with 
CFS/ME have shown a cortisol production lower than normal (Demitrack, et al., 1991). 
Because cortisol suppresses inflammation and the activation of cell-mediated immunity, a 
reduction in circulating cortisol could alter the control of these processes. 
A defect in the synthesis and/or release of corticotropin-releasing hormone (CRH), involved in 
HPA activation, has been hypothesized to contribute to the development of fatigue in subjects 
with CFS/ME. Indeed, an alteration of CRH pathways was observed in various chronic diseases 
characterized by fatigue such as Systemic Lupus Erytematosus (LES), Rheumatoid Arthritis 
(RA), Multiple Sclerosis and fibromyalgia (Clauw and Chrousos, 1997; Swain, 2000). Most 
clinical features observed in patients with CFS/ME are similar to those found in patients with 
fibromyalgia, suggesting that the pathophysiological mechanisms may be the same (Aaron et 
al., 2000). 
 
Genetic hypothesis. Evidence supports the possibility that genetic predisposition may enhance 
the development of CFS/ME. First-degree relatives of CFS/ME patients are more likely to be 
affected by the same disease than unrelated individuals (Walsh et al., 2001; Albright et al., 
2011). Studies on twins suggest that monozygotic twins are more prone to be infected than 
heterozygous ones (Buchwald et al., 2001; Sullivan et al., 2005). Furthermore, HLA-DQA1 * 
01 and HLA-DR4 haplotypes of the class II MHC (Major Histocompatibility Complex) appear 
to be risk factors for the development of CFS/ME (Smith, et al., 2005). 
 
Intestinal dysbiosis hypothesis. Subjects with CFS/ME also suffer gastrointestinal symptoms, 




intestinal microbial composition (Frissora and Koch, 2005; Riedl et al., 2008). Indeed, the 
current hypothesis is that in CFS/ME patients some bacterial species are substituted by others 
able to bind to the same sites of adhesion and induce signals that alter the pre-existing 
equilibrium. The co-morbidity of CFS/ME and gastrointestinal symptoms has been well proved, 
with one study reporting that 92% of CFS/ME patients also exhibited IBS (Aaron et al., 2000). 
Consistently, previous studies have shown an altered composition and reduced biodiversity of 
oral and intestinal microbiota in CFS/ME patients. 
A higher relative abundance of Leptotrichia, Prevotella and Fusobacterium genera and a 
decrease in the abundance of Haemophilus, Veillonella and Porphyromonas genera were 
observed in the oral microbiota of CFS/ME patients compared to healthy controls (Wang et al., 
2018). Sheedy and colleagues (2009) found a significant increase in D-lactic acid producing 
Enterococcus and Streptococcus species in CFS/ME patients. An association between the 
increase of Enterococcus species, D-lactic acid production and the severity of neurological and 
cognitive deficits was found in subjects with lactic acidosis (Stolberg et al., 1982). A study 
conducted on subjects with CFS/ME from Belgium and Norway showed a different 
composition of the intestinal microbiota between Norwegian CFS/ME patients and healthy 
controls: in particular, subjects with CFS/ME showed a significant increase in Lactonifactor 
and Alistipes genera, paralleled by in the decline of genera belonging to the Firmicutes phylum 
(Roseburia, Dialister, Holdemania, Synthophococcus) (Fremont et al., 2013). A correlation 
between the symptoms of post-exertion malaise in subjects with CFS/ME and bacterial 
translocation from the intestine to the systemic circulation was found analyzing the bacterial 
composition of blood and fecal samples before and after physical exercise. CFS/ME patients 
showed an increase in the relative abundance of Firmicutes and a reduction of Bacteroidetes in 
the bloodstream, while in fecal samples the situation was reversed (Shukla et al., 2015). 
Giloteaux and colleagues (2016) observed high levels of some markers for microbial 
translocation (LPS, LBP and sCD14) in the bloodstream of subjects with CFS/ME and reduced 
biodiversity of intestinal microbial communities. Recently, an increase in the abundance of 
Alistipes and a reduction of Faecalibacterium were observed in individuals with CFS/ME and 
IBS; instead, a decrease of Bacteroides vulgatus and a higher abundance of unclassified 
Bacteroides were observed in CFS/ME patients without IBS (Nagy-Szakal et al., 2017). 
It has been suggested that intestinal dysbiosis promotes or is associated with an altered 
permeability of the intestinal epithelial barrier. The destruction of the junctional complexes in 
the intestinal epithelium would provide a gateway for the translocation of bacteria (or some of 
their components) into mesenteric lymph nodes or systemic circulation (Shen et al., 2011; 




inducing the production of pro-inflammatory mediators and cytokines that can further damage 
the intestinal epithelium (Turner, 2009). Experimental studies have shown that chronic 
intestinal inflammation caused by bacterial products can lead to a neurological disease; the 
lipopolysaccharide (LPS) of bacterial derivation would play a central role in the generation of 
reactive antibodies against the host's lipoproteins [83] (Vogel et al., 2013). 
 
 
1.1.3 Diagnosis and therapy 
In Italy the CFS/ME is poorly known and 
diagnosed. Most problems related to CFS/ME 
diagnosis depend on the lack of specific 
biomarkers and diagnostic tests, due to the 
great heterogeneity of CFS/ME populations. 
Indeed, the diagnosis is based on several 
criteria, such as the Oxford (Sharpe et al., 
1991), Fukuda (Fukuda et al., 1994), and 
International Consensus Criteria (ICC) 
classifications (Carruthers et al., 2011), that 
identify the main symptoms of CFS/ME 
excluding other clinical conditions that 
present the same symptomatology (Table 1). Particularly, the main feature for CFS/ME 
diagnosis is a persistent fatigue that lasts for not less than 6 months, accompanied by at least 4 
of the following 8 minor symptoms: severe memory and concentration disorders, pharyngitis, 
pains in the cervical lymph and axillary nodes, muscle pain, joint pain without swelling or 
redness, headache, non-restorative sleep, post-effort discomfort lasting more than 24 hours. 
The Oxford criteria consist of two major criteria and eleven minor criteria (symptoms and 
objective signs). The record of both the major criteria and at least eight out of the eleven minor 
criteria is necessary to CFS/ME diagnosis. The objective criteria consist of: fever recorded by 
a doctor, non-exudative, modest pharyngitis, latero-cervical or axillary lymphadenopathy 
(Sharpe et al., 1991). 
According to Fukuda, the first major criterion is the onset of debilitating, persistent or recurrent 
fatigue which does not resolve resting in bed, reduces the daily patient’s activities of at least 
50%, and lasts for at least six months.  The second major criterion requires the exclusion of 
TABLE 1 - EXCLUSION CLINICAL CRITERIA 
FOR THE CHRONIC FATIGUE SYNDROME 
  
- Oncological diseases 
- Autoimmune / rheumatological diseases 
- Infections: local, occult or systemic, subacute, 
chronic from bacteria, fungi, parasites, viruses 
(including HIV and chronic hepatitis) 
- Psychiatric disorders: bipolar depression, 
schizophrenia, dementia, anorexia or nervous bulimia 
- Chronic inflammatory disorders (eg. 
granulomatosis of Wegener, sarcoidosis) 
- Neuromuscular diseases (eg myasthenia gravis, 
sclerosis multiple) 
- Endocrine disorders: hypothyroidism, d. of 
Addison, d. of Cushing, IDDM 
- Drug addiction (alcohol, drugs, psychotropic 
drugs) 
- Chronic diseases: cardiac, gastrointestinal, hepatic, 




other clinical conditions that could produce the same symptomatology. Following Fukuda’s 
classification, objective criteria are not necessary for diagnosing CFS/ME (Fukuda et al., 1994). 
Minor criteria include: low-grade fever or chills, pharyngodynia, laterocervical or axillary 
lymphadenopathy, generalized myasthenia, myalgia, arthralgias migrants without arthritis, 
headaches, disorders of sleep, generalized prolonged fatigue after exercise, neuropsychological 
disorders (photophobia, amnesia, irritability, mental confusion, concentration difficulty).  
 
Currently, there is no effective therapy for CFS/ME. Both pharmacological and non-
pharmacological (cognitive-behavioral and rehabilitative) therapies are usually applied. Non-
pharmacological therapy is based on the emotional support of the patient, reduction of 
symptoms and improvement in the quality of life. Drug therapy involves the use of psychotropic 
(sedatives, anxiolytics, antidepressants), immunomodulating (immunoglobulins) and cortisone 
drugs, non-steroidal anti-inflammatory drugs (NSAIDs) and antivirals. 
In recent years, attempts have been made to treat the disease by probiotic oral and rectal 
administration. Improvements in the majority of CFS/ME patients following bacteriotherapy 
by rectal infusion of enteric bacteria were reported in a study carried out on subjects with 
fibromyalgia, IBS and CFS/ME (Borody et al., 2012). In two other studies, slight improvement 
in certain symptoms was observed in patients following oral probiotic therapy (Sullivan et al., 















1.2. The human microbiota 
The human microbiota is the set of microbial populations constituted mainly by commensal, 
symbiotic and pathogenic bacteria and other micro-organisms - Archaea, Eukarya, fungi and 
viruses - that colonize humans at birth and from which the host organism depends for various 
functions (Nicholson et al., 2012; Kau et al., 2011). 
The microbiota is transferred from mother to child at birth and affects the life and health of the 
child with epigenetic effects. Recent evidence suggests that the microbial colonization of the 
gut starts before birth, as revealed by the placental microbiome profile (Aagaard et al., 2014). 
The infants born with natural birth have a microbiota containing species derived from the 
vaginal microbiota of their mothers. Conversely, in the case of cesarean section, the microbiota 
is similar to the skin microbiota, with many environmental bacteria that colonize the newborn 
together with those of maternal origin (Dominguez- Bello et al., 2010). 
Birth mode seems to influence immunological maturation through the development of the 
microbiota. Children born by cesarean section were found to have a higher number of antibody-
secreting cells (Clemente et al., 2012). Moreover, also human milk is involved in the 
development of both the intestinal microbiota and immune system: milk contains several 
bioactive substances and immunological components that control the maturation of the newborn 
intestine and the composition of the microbial community. Breastfeeding has a protective role 
in infants, provided by a complex mixture of molecules (lysozyme, IgA, alpha-lactalbumin, 
lactoferrin, free oligosaccharides, complex lipids) (Gordon et al., 2012).  
The stabilization of the microbiota is achieved around 3 years of age (Dominguez- Bello et al., 
2010). During the course of life the microbial communities increase linearly their diversity in 
relation to several modulating factors (age, diet, lifestyle, geographical location, genotype, drug 
intake) (Thursby and Juge, 2017). A total of 10-100 billion microbial cells dwell into the whole 
human body, except the circulatory system and the brain, for a bacterial/human cells ratio of 
10:1 (Ursell et al., 2013). The human genetic materials and those of its microbiota form the 
human metagenome. The totality of the genes that the microbiota is able to express is called 
microbiome, with a bacterial/human genes ratio of 1000:1 (Qin et al., 2010). The human 
metagenome constitutes a dynamic entity, conditioned by the diversity of microbial species in 
symbiosis with humans. The host genome determines the availability of adhesion sites for 
microorganisms in different parts of the body; indeed, new species of bacteria are always 
available and ready to bind previously occupied sites which have become available. In its turn, 
the level of expression of many host’s genes depend on the microbial composition, which 




Given the importance of this symbiosis and its implications for human health, the Human 
Microbiome Project was started in 2008 by the National Institutes of Health (NIH) whose 
purpose is the cataloging of the human microbiome and the analysis of its role in health and 
disease (hmpdacc.org/). The human microbiota harbors in several body districts: the intestine, 
oral cavity, nasopharyngeal tract, skin and urogenital tract (Fig. 2). 
Eubacteria are the most abundant group and are represented by about 1000 species, of which 
less than 200 species live in each individual (HMP Consortium, 2012). The oral and gut 
microbiota are the most complex microbial community in the human body and are closely 




Figure 2. Human microbiota composition. The figure illustrates the distribution of bacterial communities in different body 
sites. (Imagine retrieved from Cho I. and Blaser MJ, Nature Reviews Genetics, 2012) 
 
 
The oral cavity represents the gateway for bacteria at the first contact of the newborn with the 
external environment and then the colonization involves the gastrointestinal tract. Oral 
microorganisms form one of the most diverse microbiota in the human body and include 
bacteria, archaea, fungi, viruses and protozoa. The oral microbiota is directly in contact with 
the external environment and subjected to modifications that affect the composition of the 




www.homd.org) catalogs and shares information on the microorganisms of human oral cavity. 
Bacteria are predominant and about 1000 species are found in the mouth. Particularly, the most 
representative phyla are: Firmicutes, Proteobacteria, Actinobacteria, Fusobacteria, TM7 and 
Spirochaetes (Wade, 2013). The oral bacterial communities include both obligate aerobes and 
facultative and obligate anaerobes, able to degrade sugars and proteins, and several complex 
substrates derived from them. Many oral bacteria are facultative anaerobes, the two most 
numerous genera being Actinomyces and Streptococcus, while obligate aerobes are few, mostly 
Rothia and Neisseria species (Diaz et al., 2006).  
Interestingly, the composition of the oral microbiota does not vary among populations that live 
in different geographic areas (Nasidze et al., 2009). 
The intestinal microbiota is the most complex symbiotic community, including 70% of all the 
microorganisms dwelling in the human body. The composition of the intestinal microbiota 
changes through the digestive tract (Table 2).  
 
Table 2. Main habitats of the human gastrointestinal tract and resident bacteria. 
Districts Resident bacteria Abundance 
Stomach Helicobacter pylori, Steprococcus, 
Lactobacillus. 
102 - 103 CFU/mL 
Small 
intestine 
  Bacteriodes, Ruminococcus, 
Clostridium, Caprococcus, 
Streptococcus, Lactobacillus 









109 - 1014 CFU/mL 
 
 
Particularly, the colon is the most densely populated tract including 1014 bacterial cells 
belonging to between 300 and 1000 different species (Thursby and Juge, 2017). The dominant 
phyla in the human gut are Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria. 
Most bacteria belong to the genera Eubacterium, Bacteroides, Faecalibacterium, Clostridium, 
Ruminococcus, Bifidobacterium and Peptostreptococcus, while other genera, such as 
Lactobacillus and Escherichia, are present to a lesser extent. Species belonging to the genus 




varies between individuals in relation to several factors. Among these, the diet is certainly the 
most important modulating factor of intestinal bacterial diversity, influencing its functional 
relationships with the host (Arumugam et al., 2011).  
The intestinal microbiota can be divided into three large groups, called enterotypes (Arumugam 
et al., 2011), based on the greater relative abundance of one of three bacterial genera: 
Bacteroides (enterotype 1), Prevotella (enterotype 2), Ruminococcus (enterotype 3) (Fig. 3). 
The different composition of the microbiota assimilable to enterotypes is observed inside the 
colon. An individual’s enterotype does not depend on nationality, sex, age or body weight, but 
exclusively on diet. Bacteroides and Ruminococcus enterotypes are associated with either lipid- 
or protein-rich diets, while Prevotella with carbohydrates. Indeed, the western, meat-based 
lifestyle is associated with enterotypes 1 and 3, while vegetarian/vegan, cereal-based diets are 
associated with enterotype 2 (Gorvitovskaia et al., 2016). 
 
 




1.2.1 Factors that modulate the intestinal microbiota composition 
As mentioned above, there are several factors that play an important role in the development 
and modeling of a normal intestinal microbiota. Diet is certainly one of the main factors 
modulating the composition of the microflora, together with age, sex, ethnicity, genotype, 
environmental conditions and the use of antibiotics (Thursby and Juge, 2017). 
A study conducted on African and European children recorded significant differences in 
intestinal microbial composition between European children and those of an African rural 
village in Burkina Faso. African children showed higher prevalence of Bacteroidetes and 




while in European children Firmicutes and Bacteroides prevailed. These differences are related 
to the diet of the two populations: European children’s diet was rich in animal protein, sugars, 
starch, fat and poor in fibers, while African children ate foods rich in fibers (De Filippo et al., 
2010). 
Many studies have shown the existence of sex-related differences regarding the composition 
and function of the intestinal microbiota. These variations, partly driven by sex hormones, lead 
to differences between the two sexes that relate to immunity and susceptibility to various 
diseases (Vemuri et al., 2019). 
Even antibiotics are able to alter the composition of the intestinal microbiota, inducing positive 
effects, such as increased abundance of beneficial bacteria. However, a growing evidence 
suggests that the excessive use of antibiotics can lead to the development of diseases caused by 




1.2.2 Role of microbiota in health 
The term “eubiosis” indicates a state of balance in the intestinal microbial ecosystem. In a state 
of eubiosis, the intestinal microbiota is characterized by beneficial species, mainly belonging 
to the phyla Firmicutes and Bacteroidetes, while potentially pathogenic species, such as the 
Proteobacteria (Enterobacteriaceae) are present in a very low percentage (Zhang et al., 2015). 
The beneficial bacteria protect the intestinal mucosa, facilitating the digestive and assimilative 
processes. The balance between the various groups of these bacteria is essential for health. 
Oral health has a great impact on host health and is strongly influenced by oral microbiota, 
which, in its turn, plays a major role in metabolism, nutrient digestion and immune response 
(Moye et al., 2014; Slocum et al., 2016). The most important functions of oral microbiota are 
nutritional. The primary substrates for bacterial growth in the mouth are derived from saliva in 
the form of glycoproteins rather than from the food. Streptococcus species have both glycosidic 
and endopeptidase activity and are both able to degrade oral glycoproteins (Byers et al., 1999; 
Homer et al., 1990). Members of the genera Porphyromonas and Prevotella also have 
endopeptidase activity, resulting in the cleavage of proteins to peptides (Bao, et al., 2008). 
Fusobacterium and Peptostreptococcus exhibit aminopeptidase activity and can ferment amino 




In a status of equilibrium, which can be identified with healthy conditions, the gut microbiota 
is involved in the host’s metabolism, immunomodulation, pathogen resistance, maintenance of 
intestine structure/function and nutrition (Nicholson et al., 2012; Kau et al., 2011).  
The intestinal microbiota is particularly involved in the degradation of complex carbohydrates 
(Rowland et al., 2018). The intestine acts as a bioreactor for carbohydrates (Fig. 4). Humans 
absorb simple sugars in the small intestine, but their ability to digest polysaccharides is low. 
Undigested polysaccharides (i.e. cellulose, xylan, undigested starch or endogenous glycans 
such as mucins and glycosphingolipids) pass through the distal parts of the small intestine 
(ileum) and the colon and are degraded by the microorganisms of the intestinal microbiota. 
Many intestinal bacteria have a high number of enzymes (i.e glycoside hydrolases, 
polisaccharide lyases, carbohydrate esterases) which allow them to use undigested 
carbohydrates as food. 
 
 
Figure 4. Representation of host and bacterial contributions to carbohydrate utilization in the intestine. (Imagine retrieved 
from Hooper L.V. et al, Annu. Rev. Nutr., 2002) 
 
The result of this degradation is the formation of monosaccharides which are then converted 
into bacterial fermentation products such as short-chain fatty acids (SCFAs: acetic, lactic, 




Released monosaccharides and produced SCFAs can then be absorbed and used by the host. 
The bacterial production of SCFAs is involved in the regulation of intestinal trophism, 
promoting the proliferation and differentiation of the intestinal epithelium, and play an 
important anti-inflammatory role.  
The microbiota also contributes to the synthesis of B vitamins (in particular, B12) and growth 
factors (Rowland et al., 2018), metabolism of lipids and proteins and degradation of various 
polyphenols introduced through the consumption of fruit and products derived from plants 
(Jandhyala et al., 2015). Moreover, the microbiota is also able to metabolize xenobiotics and 
drugs (Jandhyala et al., 2015). 
Intestinal bacteria play an important role in the maturation and regulation of the immune 
system. Through a mechanism called immunomodulation, the microbiota helps the 
development and maturation of GALT (the lymphoid tissue associated to the intestine) and the 
organization of Peyer plaques and isolated lymphoid follicles (Jandhyala et al., 2015). 
Commensal microorganisms are necessary for the maturation of the immune system, which 
learns to distinguish commensal bacteria from pathogens through the toll-like receptors (TLR) 
of the epithelial and lymphoid cells of the small intestine (Lazar et al., 2018).  
TLRs repress the occurrence of inflammatory processes and promote immunological tolerance 
to normal microbiota components. They recognize different general microbe-associated 
molecular patterns (MAMPs) and activate the innate intestinal immunity (Francino, 2014). 
After that, a complex cascade of signals is started, causing the release of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB), which activates several genes coding for 
chemokines, cytokines, acute phase proteins, and other effectors of the humoral immune 
response (Belkaid and Hand, 2014; Thomas and Versalovic, 2010).  
Soon after birth and throughout life, the intestinal microbiota stimulates the development of the 
immune system and acts as a barrier against the proliferation of pathogens by inhibiting the 
pathogens’ adherence and colonization and the production of bacteriocins and other toxic 
metabolites (mechanism known as "colonization resistance" or "competitive exclusion") 
(Kamada et al., 2013).  
The intestinal microbiota is involved in the regulation of the Central Nervous System (CNS) 
through the microbiota-gut-brain axis (Zhul et al., 2017), a bi-directional communication 
between the microbiota, the Central Nervous System (CNS), the autonomic and enteric nervous 
system and the hypothalamic-pituitary-adrenal (HPA) axis through neurological, endrocrine 
and immunological pathways (Fig. 5). The intestinal microbiota synthesizes a large number of 
chemical compounds which can reach distant sites, such as the brain, through the blood stream, 




intestinal bacteria are able to produce several metabolites, including neurotransmitters such as 
dopamine, serotonin and GABA, which play an important role in the chemical signaling 
between the microbiota itself and the brain (Clarke et al., 2014). Therefore, alterations in the 
composition and abundance of intestinal microorganisms can influence both the enteric nervous 
system and the CNS, affecting cognitive and behavioral functions (Zhul et al., 2017).  
 
 
Figure 5. Microbiota-gut-brain axis. The gut microbiota regulates the release of cytokines TNFα, IL-1 and IL-6, by the cells of 
the enteric immune system into the bloodstream, which reach the brain and stimulate the release of CRF from the 
hypothalamus. CRF actives the anterior pitutary and the release of ACTH that induces the adrenal cortex to release cortisol. 
Abbreviations: CRF corticotrophin-releasing factor, ACTH adrenocorticotropic hormone, LPS lipopolysaccharide, DC dendritic 
cell, BC B cell, IL interleukin, TNF tumor necrosis factor α. (Imagine retrieved from Cussotto S. et al, Frontiers in 
Neuroendocrinology, 2018) 
 
1.2.3 Role of microbiota in disease 
Recently, several studies have pointed out the important role played by the microbiota in host 
health and, conversely, its contribution to disease development (Robinson et al., 2010; Bassis 
et al., 2013). 
An alteration of the microbial composition, in terms of changes in species numbers and their 
prevalence, causes the loss of homeostasis, a condition called “dysbiosis”, which can lead to 
the dominance of pathogenic species and increase in harmful compounds. In dysbiosis 
condition, the genetic coding of useful molecules is lost and harmful metabolites are produced 
by pathogenic microorganisms, affecting the pathogenesis of diseases and causing intestinal 
inflammation. 
Changes in intestinal microbial composition may be due to various factors such as infections 
by pathogenic bacteria, viruses or fungi, excessive use of drugs and antibiotics and also different 




permeability and alteration of motility and gastrointestinal secretions. Through these 
physiological mechanisms, stress can alter the microbiota, inducing the release of stress 
hormones by microbial communities which can enhance the growth of specific pathogens and 
their ability to adhere to the intestinal mucosa (Diaz et al., 2011). 
Some bacterial species that colonize the oral cavity are potentially pathogenic. The oral 
microbiota is responsible for the three commonest oral diseases in humans, periodontitis 
(Darveau, 2010), gingivitis (Zijnge et al., 2010), tooth decay (Kaur et al., 2013). Several studies 
have described the association of oral microbiota also with non-oral diseases such as respiratory 
infection (Raghavendran et al., 2007), pancreatic (Cavestro et al., 2016) and intestinal diseases 
(Kuehbacher, 2008). Changes in the intestinal microbial composition have been detected in 
metabolic diseases such as type 2 diabetes (Qin et al., 2012) and obesity (Ridaura et al., 2013), 
IBS (Labus et al., 2017; Tap et al., 2017), IBD (Manichanh et al., 2006; Maukonen et al., 2015), 
autoimmune conditions (Marasco et al., 2016; Hevia et al., 2014), cancer (Wu et al., 2009) and 
in several neurological disorders such as Parkinson's disease (Scheperjans et al., 2015), 
Alzheimer's disease (Zhuang et al., 2018) and autism  (Finegold et al., 2010), highlighting that 
there is a strong correlation between dysbiosis and the pathological condition.  
Alterations in the prevalence of several genera belonging to Lachnospiraceae family 
(Firmicutes) and an increased prevalence of Bacteroides have been described in Chron’s 
disease (Manichanh et al., 2006), ulcerative colitis (Maukonen et al., 2015) and Systemic Lupus 
Erythematous (Hevia et al., 2014). Culture-based analysis revealed that the levels of 
Fusobacterium and Porphyromonas were significantly higher in subjects with oral squamous 
cell carcinoma compared to healthy controls (Nagy et al., 1998).  
Knowledge of microbiota composition can be a key factor for the identification of a disease and 
choice of the most appropriate treatment. Currently, therapeutic measures and protocols based 
on the manipulation of intestinal microbial composition are used for the treatment of several 
pathological conditions. In recent years, the use of probiotics, prebiotics and fecal microbiota 
transplantation has become increasingly popular (Bergmann et al., 2014; Leshem et al., 2019). 
Probiotics are defined by The World Health Organization as living microorganisms which are 
able to confer benefits to the host if taken in the correct quantity. They mimic normal 
physiological conditions, enhancing the development the beneficial bacteria and hence 
promoting health by reinforcing the intestinal barrier, stimulating immunity, producing 
vitamins and antioxidants and controlling the overgrowth of pathogens (Santocchi et al., 2016). 
The most used probiotics are Bifidobacterium and Lactobacillus species (Fond et al., 2015). 
Prebiotics occur in food characterized by the presence of non-digestible oligosaccharides, such 




composition of gastrointestinal microbiota, promoting the growth and activity of beneficial 
bacteria. 
In recent years, the transplantation of fecal microbiota is gaining increasing interest for its 
potential use in humans as a therapeutic measure against diseases associated with intestinal 
dysbiosis. This strategy has been applied for the treatment of colitis caused by Clostridium 
difficile, but some studies show that it can also be used for the treatment of obesity, diabetes, 
depression and chronic inflammatory diseases (Bakker and Niewdorp, 2017; De Groot et al., 
2017). 
The main advantage of fecal microbiota transplantation is to reduce the risk of inducing 
antibiotic resistance in highly pathogenic bacteria. In addiction, this strategy is relatively 
inexpensive, being a non-pharmacological medical treatment. However, fecal transplantation 
represents an invasive method, compared to conventional treatment with antibiotics, and a risky 
strategy due to the possible transmission of infections (bacteria, viruses, intestinal parasites). 
Evidence relating to the safety of fecal transplantation is relatively limited. This is because the 
inclusion of this method in clinical practice took place very quickly and before large long-term 
prospective studies had been carried out, normally foreseen to evaluate the safety of new 
interventions. In general, fecal transplantation has been shown to be safe and effective in the 
short term, while data on long-term safety are still limited and it is not yet clear how the 
introduction of the microbiota affects the physiology of the host in the long term (Kelly CR et 
al., 2015). In recent years, several research teams have been trying to find the "ideal" fecal 
sample for the treatment of certain pathologies such as the immune-mediated ones, thanks to 
the strong link between immunity and microbiota. 
The administration of probiotics and prebiotics and the use of fecal transplantation for the 
treatment of diseases aim to enrich the intestinal microbial ecosystem with beneficial bacteria, 











1.3 Methods for the characterization of microbiota by sequencing 
To date, the study of microorganisms has been carried out mainly according to a culture-
dependent approach that is through the cultivation of microorganisms in culture media, mainly 
based on the morphological identification of microbial colonies and functional analysis by 
biochemical assays. However, the application of traditional microbiological techniques does 
not allow the identification of all the microorganisms really dwelling in a certain habitat, 
because the majority of microbial species (96-99%) cannot be cultivated in the laboratory 
(Hugenholtz et al., 1998).  
Recently, new molecular technologies have provided the basis for a more efficient microbial 
identification.  
 
1.3.1 Metagenomic analyses 
Metagenomics is a branch of genomics that studies a complex community of microorganisms 
directly accessing to their genetic contents and avoiding growth on selective culture media 
(culture-independent method). The overcoming of classical microbiology techniques for the 
identification of microorganisms involves the use of total genomic DNAs extracted from 
various matrices (soil, wood, oil, milk, ocean sediments, water sampled in different parts of a 
river's course, agricultural silage, stone fragments taken from monuments) and the sequencing 
of genomic regions, amplified by "universal" primers the target of which are gene sequences 
conserved among the organisms of interest. Most used regions are those encoding the 
hypervariable regions of the 16S rRNA gene. In this way, it is possible to depict to a larger 
extent the diversity of bacterial communities occurring in different habitats. Moreover, 
metagenomic analysis allows to study how the various microorganisms interact with each other 
and the environment and determine the specific functions of a microbial community. 
 
1.3.2 16S rRNA gene 
The 16S rRNA gene is ca. 1540 bp long and consists of 10 conserved regions and 9 
hypervariable regions (V1-V9) (Fig. 6). The product of 16S rRNA is the minor subunit 30S of 
prokaryotic ribosomes (Srinivasan et al., 2015). 
Occurring in all bacteria and archaea, the 16S rRNA gene is widely used as a phylogenetic 
marker to examine microbial diversity and identify and classify microorganisms. It is not 




different bacterial species. Moreover, the presence of several highly standardized and updated 
16S databases allows the prompt identification of bacterial species. 
 
 
Figure 6. 16S rRNA gene. Subdivision of hypervariables regions within 16S rRNA gene. 
 
NGS analysis is carried out selectively on some hypervariable regions. Indeed, some of the nine 
hypervariable regions, and in particular V1-V2 and V3-V4 regions, are more informative than 
others (Yu and Morrison, 2004) and allow a more reliable taxonomic assignment than others 
(Liu, et al, 2008). 
Several NGS platforms are used for the global analysis of abundance and diversity of complex 
microbiomes (i.e pyrosequencing Roche-454, Illumina, SOLiD). The individual hypervariable 
sequenced regions are grouped into "Operational Taxonimic Units" (OTUs), i.e. taxonomic 
clusters of sequences based on sequence similarity. Taxonomic identification is based on the 
sequencing of the nine hypervariable regions of the 16S rRNA gene. 
 
1.3.3 First generation sequencing methods 
Sanger’s method, also known as chain termination method, is the first enzymatic sequencing 





This technique is based on the use of modified nucleotides (ddNTP), characterized by the 
substitution of ribose with dideoxyribose, that prevents binding to other nucleotides. The PCR 
requires multiple copies of a DNA fragment that acts as template, a DNA polymerase, a primer 
for DNA synthesis, the four types of deoxynucleotides triphosphates (dATP, dGTP, dCTP and 
dTTP) and ddNTPs, labeled radioactively or with fluorochromes of different colors. Whenever, 
occasionally and randomly, ddNTPs are included in the DNA chain, that is forming on the basis 
of one of the DNA template fragments, the reaction ends irreversibly. The amplification of the 
DNA template provides a plethora of fragments of different length, each of which ends with a 
particular labeled ddNTPs. Subsequently, DNA fragments are split according to their length by 
gel electrophoresis. During the electrophoretic run, the fragments are excited by a laser source, 
thus allowing the formation of a particular trace. This is analyzed by a specific software, which 
translates it into a sequence of nucleotides. The type of base is identified based on the color of 
the fluorochromes recorded during the electrophoretic run. The position of the bases is 
reconstructed from the order of the fragments at the end of the electrophoretic run. The 
advantage of this method is the ability to sequence relatively large (> 700 bp) amplicons with 
low error rates. 
 
The most common technique used among culture-independent methods is the Polymerase 
Chain Reaction–Denaturing Gradient Gel Electrophoresis (PCR–DGGE). DGGE of PCR-
amplified 16S ribosomal DNA (rDNA) fragments has been frequently applied to the 
fingerprinting of bacterial populations in many fields, such as soil, sea and clinical samples. 
(Strathdee and Free, 2013) 
This technique involves the DNA extraction from samples, the amplification of 16S rDNA 
genes with bacterial specific primers, the electrophoresis on acrylamide gel containing a vertical 
gradient denaturant (urea and formamide). 
The DGGE technique is based on the separation of PCR products of the same molecular weight 
but with a different nucleotide sequence. This separation of double-stranded DNA (dsDNA) 
fragments takes place based on the principle that dsDNA molecules, subjected to a gradient of 
chemical denaturing agents (urea and formamide), undergo denaturation and therefore a change 
in conformation that slows down the migration speed on the gel. Particularly, during 
electrophoresis, the DNA fragment remains double-stranded until it reaches the area of the gel 
corresponding to its melting temperature (Tm). At this point, the fragment is partially denatured 
and therefore has a reduced electrophoretic mobility. The complete dissociation of the dsDNA 
is prevented by the addition to the 5 'end of the forward primer of a tail formed by about 40 




All PCR products, loaded on DGGE gel, dissociate in different points of the denaturing gradient 
and are distinguishable based on the different electrophoretic migration, thus determining a 
microbial composition profile. After gel staining, the number of bands is indicative of the 
number of microbial species present in the initial sample, providing an estimate of microbial 
diversity in a given ecosystem. Finally, it is possible to obtain taxonomic information since the 
bands can be excised from the gel, re-amplified and sequenced. 
However, DGGE has numerous disadvantages: variable efficiency of metagenomic DNA 
extraction; amplification errors and heteroduplex formation during the PCR reaction. In 
addition to this, only small fragments (<500 bp) can be separated in DGGE and this strongly 
limits the sequence information.  
In the last years, Sanger’s and DGGE methods have been gradually replaced by new generation 
technologies. 
 
1.3.4 Next Generation Sequencing (NGS) platforms 
NGS techniques are based on sequencing by synthesis and requires the amplification of DNA 
fragments in clusters that are subsequently anchored on microplates and introduced into a flow 
cell where sequencing reactions take place. A primer is extended cyclically by adding one or 
more nucleotides during the amplification and the sequence is read at each step of DNA 
synthesis. 
Currently available methods differ in the strategy used for amplifying the sequences, in the 
chemistry used and in the length of reads. Major benefits of NGS platforms are 1) the possibility 
of sequencing up to several million DNA fragments in parallel, 2) elimination of the cloning 
phases prior to sequencing, now replaced by a ligation of specific adapters and subsequent 
amplification, 3) increase of sequencing speed and 4) low costs for the production of DNA 
sequences. 
Below, two NGS technologies are described: Roche-454 and Illumina sequencing. 
 
Roche-454 pyrosequencing. Pyrosequencing requires the preparation of a DNA library: DNA 
is denatured and reduced to fragments to which adapters are added by ligation; successively, 
each fragment is anchored on the surface of beads, which are incorporated in water-in-oil 
emulsions. Amplicons are generated by emulsion PCR and, finally, pyrosequencing is 
performed. This technique is based on the detection of inorganic pyrophosphate (PPi), obtained 




converted to ATP by sulfurylase. ATP is then used by luciferase to convert luciferin into 
oxyluceferin, producing a light signal that can be detected by a CCD camera. 
 
Illumina. Also the Illumina technology involves the preparation of a DNA library but, unlike 
pyrosequencing, amplification takes place through the PCR bridge. Two types of primers, 
forward and reverse, are anchored on a rigid support. The amplified filament is folded in the 
direction of the nearest primers on the support and is aligned with one of them; therefore, a 
further amplification occurs in the opposite direction. This step is repeated many times for the 
same DNA chain to obtain a cluster of amplicons folded on themselves. After that, DNA 
filaments are denatured in order to obtain single-chain and non-folded amplicons. At this point 
sequencing begins: four types of modified nucleotides (ddNTP), each containing a different 
fluorescent marker, are introduced on the platform. During the replication of amplicons, at 
every incorporation of a ddNTP in the growing chain the reaction stops. Then, the fluorescence 
emitted after the ddNTP incorporation is captured by an image acquisition system, which allows 
to show which base has been incorporated at each cycle. At the end of the acquisition, the 
support is washed and a new cycle of sequencing can start (Fig. 7). 
 
 





1.4 Metabolomic analysis 
The complexity of a biological system is based on dynamic interactions among a large number 
of cellular components, such as genes, proteins and metabolites. 
Metabolomics is the study of the metabolome, defined as the set of metabolites produced by or 
otherwise occurring in a biological system (Clish, 2015). Metabolomics allows a quantitative 
and qualitative characterization of all metabolites and to highlight their interactions. As the 
metabolic profile is strongly influenced by environmental factors (diet, environmental agents, 
drugs or other substances), metabolomics also allows analyzing the effects of the interactions 
with external agents (Clish, 2015). 
In the clinical field, metabolomic analysis allows the identification of single metabolites or 
metabolic patterns and represents a useful instrument to understand the etiology of a disease. 
Furthermore, metabolomics allows the identification of unknown metabolites (Bingol and 
Bruschweiler, 2017). Pathological phenotypes are identified by pointing out the set of 
metabolites that discriminates between different groups of subjects. Therefore, these 
metabolites can represent potential biomarkers of disease (Gebregiworgis and Powers, 2012). 
The aim of metabolomics is to study the set of metabolites of a given biological sample, which 
includes a large variety of different molecules (such as amino acids, carbohydrates, lipids and 
organic acids). These compounds occur in different concentrations and in several biofluids and 
tissues (Riekeberg and Powers, 2017). 
Different approaches and methodologies are used. Target analysis is a specific approach, based 
on the qualitative and quantitative analysis of a single compound, such as a disease marker. The 
profiling metabolite focuses on the analysis of either a group of metabolites belonging to a same 
class of compounds or a specific metabolic pathway. Target analysis and metabolic profiling 
approaches are based on previous knowledge and on the study of a small number of metabolites 
(Clish, 2015; Tan et al., 2016). 
Converserly, metabolite fingerprinting is an approach that allows to examine the largest number 
of metabolites for the definition of metabolic patterns associated with a given condition. This 
approach aims to define the metabolic characteristics that are able to discriminate between the 
groups in study. Metabolite fingerprinting is not based on previous knowledge and involves a 
large number of metabolites. 
To date, the exact number of human metabolome components is still unknown. 
The main analytical methodologies used in metabolomics are Nuclear Magnetic Resonance 
(NMR) spectroscopy and mass spectrometry (MS), often coupled with chromatographic 




The data obtained from the analysis are elaborated with dedicated software and processed by 
multivariate statistical methods that allow to identify the most significant variables for the 
characterization of a pathological condition. The final step is the chemical-physical 
identification of the metabolites, which is achieved by comparison with metabolite databases 
(such as Human Metabolome Database- HMDB). 
Applying mass spectrometry, analytes can be ionized in positive or negative and the ions are 
separated according to their mass/charge ratio (m/z) to be then represented in a spectrum with 
their intensities. MS analysis is usually coupled with chromatographic separation methods, such 
as liquid chromatography or gas chromatography, which allow to increase the analytical 
sensitivity and the number of identified metabolites. M/z ratio, retention time and intensity are 
the parameters that represent the metabolic fingerprinting of the sample under investigation 
(Fig. 8). 
Multivariate methods applied for processing metabolomic data are classified as unsupervised 
and supervised (Boccard, et al., 2010). Applying unsupervised methods, the classification of 
groups is not previously known. These methods aim to evaluate whether the comparison of 
metabolic spectra allows the discrimination of the different groups under investigation. An 
unsupervised method widely used in metabolomics is Principal Component Analysis (PCA). 
With supervised methods, the classification of groups is previously known, and the analysis 
aims to obtain a mathematical model which, based on metabolomic data, allows to identify the 
variables that discriminate between groups. The resulting model allows to predict which group 
a possible new sample belongs to. 
 
 




Online metabolic databases provide information on the chemical-physical and spectroscopic 
characteristics of known metabolites which can be compared with those of the metabolites to 
identify. The Human Metabolome Database is the most complete and contains information on 
over 40000 metabolites (www.hmdb.ca).  
More sophisticated analytical techniques are required for the accurate identification of the 
metabolites. As each element has isotopes with a characteristic mass, using high resolution 
instruments it is possible to measure the mass precisely and thus obtain very precise information 
on the composition of the examined metabolite. Another method consists in the use of 
fragmentation methods, such as MS/MS mass spectrometry: an ion, selected by the first 
analyzer, is fragmented in a collision cell and the mass analysis of its fragments is performed 
in a second analyzer. Each compound has its own characteristic fragmentation spectrum, so 

























2. RESEARCH AIMS 
 
 
The aims of my PhD were to assess the diversity of bacterial communities and map the changes 
in the composition of the oral and intestinal microbiota of adult subjects with CFS/ME 
compared to healthy subjects. My main aim was to point out whether any variation in the 
bacterial community may be somehow involved in the pathogenesis of CFS/ME and be used in 
the future for the identification of diagnostic biomarkers.  
To investigate the oral and intestinal bacterioma in ME/CFS subjects, I applied a NGS 
approach. This approach involved the direct isolation of total DNA from fecal and salivary 
samples followed by the selective amplification of bacterial DNA using specific universal 
primers for the hypervariable regions V3-V4 of the 16S rRNA prokaryotic bacterial gene. 
Amplicons were sequenced using NGS high-throughput platform (MiSeq-Illumina); finally, 
bioinformatic and statistical analyses, using dedicated software (Mothur, R), were applied for 
comparing, analyzing and interpreting sequencing data. 
In addition, a pilot study was conducted on a subgroup of CFS/ME patients which belonged to 
a same cluster at family level to evaluate whether the metabolic profile of CFS/ME patients 
differed from those of healthy subjects. The metabolic analysis was performed on fecal samples 
by an Ultra Performance Liquid Chromatography (UPLC) interfaced with a high-resolution Q-

















3. MATERIALS AND METHODS 
 
3.1 Participant recruitment and sample collection 
In this study 105 volunteers were enrolled: 35 CFS patients, 35 patients’ relatives without CFS 
living with patients, and 35 healthy controls. 
The recruitment was performed according to the following inclusion criteria: CFS diagnosis 
according to Fukuda’s criteria (Fukuda et al., 1994), age between 18 to 80 years and signature 
of informed consent. 
All participants who had used antibiotics, cortisone and non-steroidal anti-inflammatory drugs, 
inhibitors of proton pump inhibitors and probiotic drugs in the two months before the 
recruitment were excluded. Healthy control subjects and patients’ relatives who had a previous 
history of diseases associated with chronic fatigue, bacterial and viral infections, cancer, 
chronic coronary diseases and allergies were also excluded.  
Only the relatives who lived with the patients and shared similar dietary habits with them were 
enrolled. Age, sex and body mass index were matched in healthy controls. 
Twentyfive patients reported gastrointestinal symptoms and showed post-exertional malaise. 
Moreover, eleven patients also had Irritable Bowel Syndrome (IBS) diagnoses. Neither controls 
nor patients’ relatives reported this syndrome.  
In order to measure the extent and severity of fatigue and to evaluate the health status of the 
patients, CFS subjects completed the Chalder Fatigue scale (Chalder et al, 1992) and the MOS 
SF-36 Health Survey (Ware et al, 1992).  
The recruitment and sample collection were carried out at the clinic of Laboratory Magi 
EUREGIO s.c.s of Bozen, thanks to the collaboration of the Italian Association of CFS patients 
- AMCFS Onlus. Fecal and salivary samples were collected in sterile tubes by the participants 
themselves and delivered to appointed personnel for storage at -80°C within one hour. 
The study was performed in accordance with the Declaration of Helsinki and was approved by 









3.2 Intestinal and oral bacterioma analysis 
 
 
3.2.1 DNA extraction 
Fecal samples. DNA from fecal samples of all participants was extracted using QIAmp DNA 
Stool Mini kit (Qiagen, Hilden, Germany), in accordance with the manufacturer’s instructions. 
First, 180-200 mg of feces were placed in a 2 ml tube to which 1,6 ml ASL buffer was added. 
The sample was then mixed until it was homogenized and subsequently centrifuged at 
maximum speed for 1 minute. While the pellet was discarded, 1,4 ml of supernatant were taken 
and placed in a new 2 ml tube. An InhibitEX tablet was added to the supernatant in order to 
neutralize PCR inhibitors. The sample was then mixed, incubated at room temperature for 1 
minute and centrifuged at maximum speed for 3 minutes. Subsequently, all the supernatant was 
transferred to a new 1.5 ml tube and centrifuged at maximum speed for 3 minutes. In a new 2 
ml tube, 25 μl of proteinase K, 600 μl of supernatant and 600 μl of AL buffer were added. The 
tube was then vortexed for 15 seconds and incubated at 70°C for 18 minutes. After the 
incubation, 600 μl of ethanol (96-100%) were added to the lysate. Then, 600 μl of lysate were 
transferred to a new QIAamp spin column with collection tube and centrifuged at maximum 
speed for 1 minute. Finally, the tube containing the filtrate was discarded and the QIAamp spin 
column repositioned in a new collection tube. Subsequently, 500 μl of buffer AW1 were added 
to the QIAamp spin column which was centrifuged for 1 minute at maximum speed. Then, 500 
μl of Buffer AW2 were added to the QIAamp spin column, centrifuged at maximum speed for 
3 minutes. The spin column was subsequently inserted into a new 1.5 ml tube. The last phase 
of the protocol was repeated twice adding each time 100 μl of buffer AE to the QIAamp spin 
column and incubating at room temperature for 5 minutes. As soon as the incubation ended, the 
tube containing the spin column was centrifuged at 8000xg for 1 minute. Finally, the QIAamp 
spin column was discarded while the 1.5 ml tube containing the DNA was stored at -20°C. 
DNA integrity was tested by agarose gel electrophoresis. DNA integrity was evaluated by 
agarose gel electrophoresis and DNA concentration measured by Qubit HS dsDNA 
fluorescence assay (Life Technologies, Carlsbad, CA, USA). 
 
Salivary samples. DNA from salivary samples was extracted by QIAmp DNA Blood Mini kit 
(Qiagen, Hilden, Germany) in accordance with the manufacturer’s instructions as follows: 1 ml 




After centrifugation at 1800 g for 5 min, the supernatant was discarded and the pellet was 
resuspended in 180 μl of PBS. After adding 20 μl of QIAGEN Protease and 200 μl of Buffer 
AL, the sample was incubated at 56°C for 10 min. Then, 200 μl of ethanol (96–100%) were 
added to the sample, which was loaded on a QIAamp Spin Column in a 2 ml collection tube 
and centrifuged at 6000 xg for 1 min. The tube containing the filtrate was discarded and the 
QIAamp spin column was repositioned in a new collection tube. Subsequently, 500 μl of buffer 
AW1 were added to the QIAamp spin column which was centrifuged for 1 minute at 6000 x g 
for 1 min. After adding 500 μl of Buffer AW2, the QIAamp spin column was centrifuged again 
at maximum speed for 3 minutes. The spin column was subsequently inserted into a new 1.5 ml 
tube. To eluate the DNA, 100 μl of buffer AE were added to the QIAamp spin column, with 
subsequent incubation at room temperature for 5 minutes. After incubation, the tube containing 
the spin column was centrifuged at 6000xg for 1 minute.  Then, 100 μl of filtered eluate were 
used for a second elution step. Finally, the QIAamp spin column was discarded, while the 1.5 
ml tube containing the DNA was stored at -20°C. DNA integrity was tested by agarose gel 
electrophoresis. DNA integrity was evaluated by agarose gel electrophoresis and DNA 
concentration measured by Qubit HS dsDNA fluorescence assay (Life Technologies, Carlsbad, 
CA, USA). 
 
3.2.2 DNA quantification 
DNA concentration was measured by fluorimetric analysis using Qubit® HS dsDNA 
fluorescence assay (Life Technologies, Carlsbad, CA, USA). The Qubit dsDNA HS (High 
Sensitivity) protocol for DNA quantification included: the preparation of a Working Solution 
(W.S.), by diluting the reagent 1: 200 in the Qubit dsDNA HS buffer, and the preparation of the 
reference standards for instrument calibration, transferring 190 μl of W.S into two test tubes to 
which then 10 μl of “standard 1” and “standard 2” were added. Two μl of the solution containing 
extracted DNA were transferred into a 0.5 ml tube adding 198 µl of W.S to obtain a final volume 
of 200 μl. The samples were exposed to a light source to measure the DNA concentration. The 
average of three measures was calculated. To calculate the real concentration of the sample the 
following formula was applied: Sample value = QF value * (200/x), where QF is the mean 
value displayed on the fluorimeter and x is microliters of extracted DNA (1-20 μl) that were 
measured. Once the real quantity of extracted DNA was calculated, the DNA of all samples 






3.2.3 16S rRNA gene amplification and Illumina sequencing  
The PCR amplification of both the V3 and V4 regions of 16S rRNA was conducted using the 
indexed primers 343 F (5′-TACGGRAGGCAGCAG-3′) and 802 R (5′-
TACNVGGGTWTCTAATCC-3′), as described in Spigni et al. (2018). 
PCR reactions were performed in 25 μL containing 12,5 μL of Phusion Flash High-Fidelity 
Master Mix (Thermo Fisher Scientific, Inc., Waltham, MA, USA), 0,5 μM of each primer, 1 ng 
of DNA template and PCR nuclease-free water. To analyze several amplicon samples 
simultaneously in the same sequencing run, a multiplexing strategy was performed. An 
extension of nine nucleic acids was added to the 5’ end of the forward primer, with the first 
seven bases acting as a tag, to identify each sample unequivocally, and the other two bases 
acting as a linker. 
The two step-PCR method described in Berry et al. (2011) was adopted, with a first PCR step 
of 25 cycles using untagged primers, and a second PCR step of 8 cycles with tagged primers 
and 1 μL of first step products used as template. The PCR termal profile was the same in the 
two steps: 30 seconds of denaturation at 94°C, 30 seconds of primer annealing at 50°C and 30 
seconds of primer elongation at 72 °C, followed by a final elongation step of 10 minutes at 
72°C. 
The final PCR products, approximately 450 bp long, were verified by electrophoresis on 1% 
agarose gel and the concentrations of amplicons were measured by Qubit® HS dsDNA 
fluorescence assay (Life Technologies, Carlsbad, CA, USA).  
Equimolar concentrations of amplicons (35 ng/µL for faecal samples and 30 ng/µL for salivary 
samples) were pooled and the final pool was then purified with the SPRI (Solid Phase Reverse 
Immobilization Method) using Agencourt AMPure XP kit (Beckman Coulter, Italy, Milano). 
The pool was finally sent to Fasteris Company (Geneva, Switzerland) for the amplicon library 
preparation and for paired-end sequencing (2 bp x 300 bp) on MiSeq Illumina platform 
(Illumina Inc, San Diego, CA), operating with V3 chemistry. 
 
 
3.2.4 Electrophoresis on agarose gel 
The correct amplification of bacterial DNA was evaluated by electrophoretic running of all 
samples on 1% agarose gel. This technique allows the separation of charged molecules, thanks 
to the application of an electric field. The 1% agarose gel (ThermoFisher, Waltham, MA USA) 
was prepared dissolving 1 g of agarose in 100 ml TAE buffer (Biorad, Hercules, CA USA) and 




KAPA Loading Dye (6X) were added to 10 μl of amplified product.  To verify the presence of 
the expected products (459 bp), bands were visualized using a UV transilluminator.  
 
3.2.5 Dataset preparation and data analysis 
Illumina sequencing data were pre-processed for OTU- and taxonomy-based analyses. Raw 
paired reads were assembled with the “pandaseq” script (Masella et al., 2012), allowing at least 
30 bp of overlap between the read pairs and a maximum of two mismatches. Sequences were 
demultiplexed and quality-controlled with the fastx-toolkit, according to sample indexes 
(http://hannonlab.cshl.edu/fastx_toolkit/). 
Mothur v.1.39.5 software (Schloss et al., 2009) was used in order to remove sequences with 
large homopolymers (≥10), sequences that did not align within the targeted V3-V4 region, 
chimeric sequences (Edgar et al., 2011), and sequences that were not classified as bacterial after 
alignment against the Mothur version of the RDP training data set. The resulting high-quality 
sequences were analyzed with Mothur and R (http://www.r-project.org/) following both the 
OTU- and taxonomy-based approach. By the OTU approach, sequences were first aligned 
against the SILVA reference database for bacteria (Pruesse et al., 2007) using the NAST 
algorithm and a kmer approach (De Santis et al., 2006; Schloss et al., 2010), and then clustered 
in OTUs (Operational Taxonomic Units) with 97% similarity using the average linkage 
algorithm. OTUs were classified at taxonomical levels by alignment against the Greengenes 
database (McDonald et al., 2012). 
Based on OTU matrixes, the α and β diversity indices were calculated using Mothur and R 
software. α-diversity is used to measure the diversity within a sample, calculating a index for 
each sample. Different metrics based on richness, abundance and “evenness” of species were 
applied to calculate diversity indices: Observed species, Chao1 and inverse Simpson. Observed 
species index was calculated counting only unique OTUs (richness) in each sample. Chao1 and 
Simpson’s indices were calculated based on richness and distribution of species (evenness) in 
each sample. Evenness (or equitability) refers to how equally abundant species in a sample are. 
β-diversity is used to estimate the diversity between samples and provides a measure of the 
distance between each sample pair. β-diversity is calculated for every pair of samples to 
generate a dissimilarity matrix. Bray-Curtis metric, a non-phylogeny based method that takes 
abundance of species into account, was applied to calculate the indices of dissimilarity. 
The good coverage estimate was calculated to evaluate the percentage of diversity captured by 
sequencing. The most abundant OTUs identified were confirmed by BLAST (Basic Local 




Statistical analyses were carried out on OTU matrixes by using Mothur and R softwares and 
included hierarchical clustering analyses with the average linkage algorithm at different 
taxonomic levels, principal component analysis (PCA) and canonical correspondence analysis 
(CCA). Metastats, a statistical software based on non-parametric t-test, was used to compare 
OTUs between groups (Paulson et al., 2011). ANOVA, t test and post hoc Bonferroni correction 
were applied to test for any significant difference in the relative abundances of oral and 
intestinal bacterial taxa between groups. 
By PCA data from the β-diversity distance matrix were represented in two dimensional plots 
(PC1 and PC2). The distances between the samples are used to define similarities and 
differences between samples. 
 Multivariate CCA was performed on bacterial OTUs abundance table in order to assess if 



















3.3 Analysis of fecal metabolites by UPLC - MS 
 
3.3.1 Instrument and sample preparation 
The metabolic analysis was performed on selected fecal samples by a UPLC (Ultra Performance 
Liquid Chromatography) chromatographic system, characterized by short analytical time and 
high chromatographic resolution, interfaced with a high-resolution Q-ToF mass spectrometer 
(MS). 
After collection, the fecal samples were aliquoted into 2 ml tubes and then frozen at -80 °C. 
One gram of each fecal sample was put into a 15 ml tube and then 10 ml of methanol (80%) 
and 0,1 ml of formic acid were added for the extracting the compounds. After an overnight 
incubation, 15 mL tubes were centrifuged at 20000 xg for 10 minutes in order to precipitate 
insoluble materials. Subsequently, 1 mL of supernatant was filtered using a 0,22 μm cellulose 
filter and transferred into glass vials for chromatografic analysis. Quality controls (QC) were 
prepared by mixing an aliquot (40 μL) of each sample. 
 
3.3.2 Chromatographic and spectroscopic analysis 
Samples were analyzed using a chromatographic column at inverse phase. In the polar mobile 
phase, eluents used for the analysis were: solvent A: H2O + 1% Formic Acid; and solvent B: 
Acetonitrile + 1% Formic Acid. The analysis was carried out in gradient by increasing 
progressively the volume of one solvent while decreasing the volume of the second solvent. 
The non polar stationary phase was constituted by a long chain hydrocarbon anchored to a silice 
support.  
MS analysis was performed by a high-sensitivity and high-resolution Q-ToF mass 
spectrometer, capable to separate the metabolites based on their exact mass in order to identify 
the different compounds. An electrospray ionizator (ESI) was used for the ionization of 
compounds and the analyses were performed in positive ionization.  
All the samples were analysed in triplicate and injected in three random sequences in order to 
avoid any classification bias due to analytical conditions. QC were analysed together with the 
samples to verify the analytical reproducibility. Furthermore, to highlight possible 






3.3.3 UPLC-MS data extraction and statistical analyses 
Data extraction was performed through chromatogram analysis using Mass Profinder B.06 and 
Mass Profiler Professional software (Agilent, Santa Clara, CA USA). Optimization parameters 
for data extraction were obtained through the preliminary QC analysis. After extraction, data 
were analyzed according to an untargeted approach and processed in order to obtain a data set 
of identified variables. The variables were normalized on the baseline (median) and by means 
of a normalization algorithm (percentile shift at 75%). The data set was filtered in order to 
eliminate potentially uninteresting variables for subsequent analyses. 
The resulting variables were treated with "Pareto" scaling and centering on the average. A 
multivariate PCA model was used to describe the data set. The PCA is an unsupervised method 
which allows to obtain latent variables (Principal Components) which describe the variability 
among samples. The PCA permits to simplify the information contained in the original data 
matrix, and explore the distribution and similarity of the samples’ metabolic profiles 
highlighting the presence of clusters. PLS–DA (Partial Least Square - Discriminant Analysis) 
and OPLS-DA (Orthogonal Latent Structure - Discriminant Analysis) classification models 
were then applied to the data set. These supervised methods, based on previous knowledge of 
sample classification, allow to identify more clearly which experimental information is the most 
useful for discriminating between two or more groups. In the OPLS-DA model this information 
is summarized in a small number of predictive scores resulting from a combination of the 
measured variables. A VIP (Variable Importance in Projection) score is a measure of a 
variable’s importance in the OPLS-DA model and summarizes each variable’s contribution to 
the model. The VIP score is calculated as the weighted sum of the squared correlations between 
OPLS-DA components and the original variable. Weights represent the percentage variation 
explained by the PLS-DA component in the model. Compounds with a VIP score greater than 
1 are those which contribute the most to group discrimination in the OPLS-DA model.  
Relative concentrations (fold changes) of metabolites were determined by calculating the ratio 
of the average MS ion intensities (peak areas) in the experimental groups. To determine 
statistical significance of fold changes, Student’s t-test (two-tailed) and post hoc Bonferroni 
correction were applied to peak area values of biological replicates to assess any significant 
difference between groups. A p-value threshold of 0.05 was used. 
The model obtained can be interpreted in terms of the set of variables which characterize a 
specific group. The permutation test was applied to confirm the validity of the model and 







4.1 Characteristics of the study population 
The study was carried out on a total of 105 subjects: 35 patients (P) and 70 control subjects. 
The healthy control population was constituted of two distinct groups: 35 patients’ relatives (R) 
without CFS/ME and 35 healthy subjects (C) not belonging to patients’ family (Table 3).  
 
Table 3. Characteristics of study population. 









Ethnicity/Nationality  Caucasian/Italian Caucasian/Italian Caucasian/Italian 
Geographic area  Northern Italy Northern Italy Northern Italy 
Age Mean ± SD 
Median 
46,4 ± 16,1 
49 
54,4 ± 15,9 
55 
55,2 ± 18 
58 
BMI Mean ± SD 
Median 
23,1 ± 4.4 
22.6 
25,5 ± 5 
25.3 














































Chalder Fatigue Scale Range: 0-33 24,9 ± 5.1 - - 
SF-36 Health Survey 
Physical functioning: 
Role limitations due to 
physical health: 
 














Range (%): 0-100 
 
 
52% ± 2,4 
 
13% ± 3,1 
 
69% ± 4,7 
 
23% ± 1,5 
 
65% ± 1,2 
 
33% ± 2,2 
 
49% ± 2,8 
 
24% ± 1,2 
 














































Twenty-six CFS/ME patients were females and nine were males, with a mean age of 46,4 ± 
16,1 years and a BMI of 23,1 ± 4,4. Twentyfive patients (71%) self-reported gastrointestinal 
disturbances and 11 of them (31%) showed IBS comorbidity. The majority of the patients, 30 
(85%), indicated a post-exertional malaise.  
Patients’ relatives had a mean age of 54,4 ± 15,9 years and a BMI of 25,5 ± 5. Sixteen relatives 
were females and 19 were males. The control group included 26 females and 9 males, with a 
mean age of 55,2 ± 18 years and a BMI of 23,5 ± 4,7. 
Seven patients’ relatives (20%) reported gastrointestinal symptoms, while only two relatives 
(5%) showed post-exertional malaise. No external controls and patients’ relatives reported IBS 
diagnosis. All participants were Caucasian race, followed an omnivorous diet and belonged to 
the same geographical area (Northern Italy). No one was a smoker.  
CFS subjects completed the Chalder Fatigue scale (Chalder et al., 1993) and the MOS SF-36 

























4.2 Sequencing data analysis of intestinal and oral bacterial communities 
Sequences with large homopolymers (≥10), sequences <380 bp, chimeric sequences, sequences 
that did not align within the targeted V3-V4 region, and sequences that were not classified as 
bacterial after alignment against RDP database were removed. 
After the assembly and demultiplexing of the Illumina paired-end sequences, a total of 
9,967,562 and 4,774,706 raw sequences was obtained for fecal and salivary samples 
respectively. After quality trimming and chimera checking, these were reduced to 8,788,426 
and 3,508,491 filtered sequences. To avoid biases in diversity estimates due to differences in 
the number of sequences per sample, rarefaction to a common minimum number of 6,100 and 
5,200 sequences per sample, which represent the number of sequences of the lowest populated 
sample, was performed for fecal and salivary samples respectively. 
After the rarefaction step, 481,803 high quality sequences for fecal samples and 585,579 high-
quality sequences for salivary samples remained for further analyses.  
A high average Good’s coverage (98,53% ± 0,64%) was obtained for fecal samples, 
highlighting that most of bacterial diversity in the samples was represented. Conversely, in 
salivary samples the Good’s coverage index was lower (79,90% ± 1,94%). 
Subsequently, the reads were clustered in OTUs (Operational Taxonomic Units) at 97% 
similarity, without any sub-filtering for rare OTUs, and resulted in a total of 4231 OTUs for 
fecal samples and 78000 OTUs for salivary samples, with an average number of 207 and 1235 
OTUs per sample respectively (Tab. 4).  
Both in feces and saliva, a lower OTUs number was observed in patients’ relatives comparing 
to two other groups, while no substantial difference was between CFS/ME patients and the 
external control group. 
 
Table 4. OTUs average number of intestinal and oral microbiota in CFS patients, relatives and controls. Comparison of OTUs 
numbers between the three groups. Univariate (ANOVA) test is applied in order to assess significant differences between 
groups (P < 0.05). 
  OTUs average number  p-value 
(ANOVA) 
 CFS PATIENTS RELATIVES CONTROLS  
Feces 216 ± 78,04 189 ± 74,06 221 ± 60,84 0,27 
Saliva 1258 ± 97,14 1217 ± 91,50 1236 ± 139,43 0,37 
 
Based on the number of OTUs identified, to estimate the efficiency of the sequencing analysis 
the percentages of bacterial sequences correctly classified was calculated at different taxonomic 




In fecal samples all sequences were correctly classified up to the order-family levels (99%), 
with a progressive reduction at genus (77,6%) and species (31,7%) levels (Fig. 9 A). For 
salivary samples (Fig. 9 B), all sequences were correctly classified up to the class level (99,3%), 
while percentages were slightly reduced going down to the order (96,3%), family (94,8%), 




Figure 9 A-B. Percentages of bacterial sequences correctly classified at different taxonomic depth. Data refer to sequences 
identified as bacterial after PCR amplification of the V3-V4 16S rRNA region in fecal (A) and salivary (B) samples at different 
taxonomical levels. 
 
4.2.1 Intestinal microbiota diversity 
The OTUs table was used for the subsequent α- and β-diversity analyses. The diversity within 
the intestinal bacterial community in all participants was evaluated determining different α-
diversity indices (Table 5). Bacterial richness and evenness were assessed basing on Observed 





Table 5. OTU-based diversity indexes in fecal samples of the experimental groups of subjects. The table shows the total 
number of OTUs, (b) Chao index and (c) Simpson’s evenness indexes in CFS patients, patients’ relatives and external control 
group respectively. Univariate (ANOVA) test is applied in order to assess significant differences between groups (P < 0.05). 
α-diversity indices P (mean) R (mean) C (mean) 
p- value 
(ANOVA) 
Chao1 453,44 ± 194,73 366,96 ± 155,90 422,03 ± 151,23 0,14 
Observed S 215,60 ± 78,03 189,26 ± 74,06 221,43 ± 60,83 0,25 
Simpson 17,77 ± 11,12 15,62 ± 9,08 13,35 ± 7,34 0,31 
 
 
No significant difference in terms of total measured OTUs was recorded among groups despite 
the patients’ relatives showed a slightly lower richness. Chao1 and Simpson’s evenness indices 
resulted slightly increased in CFS/ME patients, although the differences were not statistically 
significant.  
Multivariate β-diversity analyses were carried out by Principal Component Analysis (PCA, Fig. 
10) and by Canonical Correspondance Analysis (CCA, Fig. 11) in order to evaluate the 
dissimilarity between the intestinal microbiome of all participants.  
No difference in β-diversity was recorded among groups. According to β-diversity indices, PCA 
results showed a full overlapping of CFS/ME patients, their relatives and external controls. 
 
 
Figure 10. Principal component analysis (PCA) of fecal microbiota compositions in the experimental groups of subjects. PCA 
was performed based on abundance of classified OTUs in CFS patients, patients’ relatives and external healthy controls, 





Microbial diversity was further examined by CCA analysis in order to assess if healthy state 
might influence the relative distribution of OTUs across individuals.  
Three partially overlapping clusters were recorded (p = 0,003), although the model explained 
only 4% of variance. CFS/ME individuals were separated from their relatives and the external 
control group along the first major axis, while the second axis separated CFS/ME patients and 
external controls from patients’ relatives.  
 
 
Figure 11. Canonical correspondence analysis (CCA) of fecal microbiota compositions in the experimental groups of 
subjects. CCA was performed based on abundance of classified OTUs in CFS patients, patients’ relatives and external healthy 
controls, respectively. The plot shows that the disease status is a significant source of variability in bacterial communities, 
explaining 4% of the variance in fecal microbiota. The percentages on each axis indicate the variation in the samples. 
Individuals are labeled according to the three groups studied. 
 
For each sequence, hierarchical clustering analysis was performed at different taxonomic levels 
in order to determine the relative distribution of different bacterial taxa among samples and 
assess the grouping of individuals. At the phylum level (Fig. 12 A) Firmicutes predominated, 
followed by Bacteroidetes, Actinobacteria and Proteobacteria. Some CFS/ME patients 
clustered separately because of a reduction in the abundance of Firmicutes mirrored by an 
increase in the relative abundance of Bacteroidetes. However, a clear separation of all CFS/ME 






Figure 12. Hierarchical clustering of classified sequences at phylum (A) and family (B) classification levels. The three 
experimental groups are indicated as M (CFS patients), F (patients’ relatives), and C (external healthy controls). Bars of 
different colors indicate the relative percentage of bacterial phyla identified in each fecal sample. Only taxa participating with 
≥5% in at least one sample are shown, while taxa with lower participations were added to the “other” sequence group. Similar 




When OTUs were classified at the family level, a partial grouping of some CFS/ME patients 
(M12-M2-M10-M7-M24) was observed, showing a higher relative proportion of 
Bacteroidaceae and a lower abundance of Lachnospiraceae (Fig 12 B).  
Metastats analysis was performed in order to determine OTUs whose relative abundance was 
significantly different between groups (Fig.13). Considering the 48 most aboundant OTUs, 
which represented the 95% of the total biodiversity in the analyzed samples, most were 
represented by members belonging to the Firmicutes phylum. Their relative abundance was 
lower in CFS/ME patients and in their relatives compared to external control subjects. 
 
 
Figure 13. Differential relative abundance of specific OTUs across the three experimental groups. Metastats model was 




OTUs classified respectively as Bacteroides vulgatus (OTU00005), unclassified Bacteroides 
(OTU00014), unclassified Romboutsia (OTU00015), unclassified Barnesiella (OTU00016), 
unclassified Ruminococcus (OTU00027), Bacteroides uniformis (OTU00030), unclassified 
Ruminococcaceae (OTU00032), Phascolarctobacterium faecium (OTU00035) were 
significantly more abundant in CFS/ME patients and their relatives, while unclassified 
Roseburia (OTU00008) was significantly less abundant in patients’ relatives than in controls. 
In addition, Ruminococcus bromii (OTU00004) was significantly more abundant in the 
patients’ relatives. 
Classification of OTUs at different taxonomic levels was carried out in order to evaluate the 
relative abundance of different bacterial taxa between samples. The significant differences 
between experimental groups in the relative abundances of intestinal bacterial taxa are reported 
in Table 6. 
At phylum level, CFS/ME patients, their relatives and external control group showed that their 
intestinal bacteria clustered within five main bacterial phyla: Firmicutes, Bacteroidetes, 
Proteobacteria, Actinobacteria and Verrucomicrobia (Fig. 14).  
 
 
Figure 14. Compositions of the intestinal microbiota from CFS patients, their relatives and controls at phylum level. Only 




































A lower abundance of Firmicutes (P = 67,17% vs R = 69,99% vs C = 78,53%) and a significant 
increase in Bacteroidetes (P = 21,16% vs R = 17,40% vs C = 10,80%) were observed in 
CFS/ME patients (p = 0,0005) compared to external controls. In addition, a decrease in 
Actinobacteria prevalence (P = 1,76% vs R = 3,60% vs C = 2,66%) and a higher proportion of 
Proteobacteria (P= 6,42% e R= 7,04% vs C= 4,45%) were also detected in CFS/ME patients 
and in their relatives (not statistically significant).  
A change in Firmicutes/Bacteroidetes ratio was observed (Fig. 15), with a reduction of about 
60% in CFS/ME patients and of 50% in their relatives compared to the external control group 
(not statistically significant).  
 
 
Figure 15. Firmicutes/Bacteroidetes (F/B) ratio in fecal samples across the three experimental groups. Comparison of F/B 
ratio between CFS patients, their relatives and external controls. 
 
In total seven orders with relative aboundance ≥ 1% in at least one sample were found, some of 
which showed significant differences among groups (Fig. 16). Among the most interesting 
variations, a lower abundance of Clostridiales (P = 64,26% vs R = 67,77% vs C = 76,95%) was 
observed in CFS/ME patients (p = 0,023) compared to external controls; conversely, 
Bacteroidales (P = 20,70% vs R = 17,12% vs C = 8,63%) were significantly more present in 
patients (p = 0,0005) and their relatives (p = 0,015).  
Other differences, not statistically significant, were observed for the orders Enterobacteriales 
(P = 4,71% vs R = 5,51% C = 2,19%), whose presence in CFS/ME patients and in their relatives 
was approximately twice compared to that found in the external controls, Actobacillales (P = 






















Bifidobacteriales (P = 0,96 % vs R = 1,82% vs C = 1,39%), which were less abundant in 
CFS/ME patients compared to their relatives and external controls.  
 
 
Figure 16. Compositions of the intestinal microbiota from CFS patients, relatives and controls at order level. Only taxa ≥1% 
in at least one sample are shown, while taxa with lower participations were added to the “other” sequence group. 
 
At family level, the ten most aboundant families in the three experimental groups were 
Lachnospiraceae, Ruminococcaceae, Veillonellaceae, Clostridiaceae, Bacteroidaceae, 
Rikenellaceae, Enterobacteriaceae, Streptococcaceae, Christensenellaceae, 
Coriobacteriaceae and Barnesiellaceae (Fig. 17). Of these, Lachnospiraceae (P = 18,07% vs 
R = 20,56% vs C = 30,11%) were reduced in CFS/ME patients (p = 0,034) compared to external 
controls; conversely, Bacteroidaceae family (P = 9,93% vs R = 6,59% vs C = 1,27%) were 
about 10 times more abundant in CFS/ME patients (p = 0,0002) and 6 times in their relatives 
(p = 0,003) respect to external controls. Another member of Bacteroidales, namely 
Barnesiellaceae (P = 1,71% vs R = 1,15% vs C = 0,27%), was significantly increased in both 
patients (p = 0,0005) and their relatives (p = 0,0089). Not statistically significant differences 
emerged for the families Rikenellaceae (P = 7,03% vs R = 7,01% vs C = 4,89%), 
Enterobacteriaceae (P = 4,71% vs R = 5,51% vs C = 2,19%), belonging to the Proteobacteria 










































Figure 17. Compositions of the intestinal microbiota from CFS patients, relatives and controls at family level. Only taxa ≥1% 
in at least one sample are shown, while taxa with lower participations were added to the “other” sequence group. 
 
At genus level, Anaerostipes (P = 0,18% vs R = 0,47% vs C = 1,15%), was significantly less 
abundant in both CFS/ME patients (p = 0,02) and their relatives (p = 0,032) compared to 
external controls (Fig. 18). In contrast, Bacteroides (P = 9,93% vs R = 6,59% vs C = 1,27%) 
and Phascolarctobacterium (P = 1,17% vs R = 0,76% vs C = 0,15%) were about 10 times more 
abundant in CFS/ME patients (p = 0,0002 and 0,004, respectively) and Bacteroides was about 
6 times more abundant in patients’ relatives (p = 0,003).  
Also Ruminococcus (P = 6,60% vs R = 11,48% vs C = 8,21%) was significantly more abundant 
in patients’ relatives (p = 0,0194). Roseburia (M = 6,61% vs F = 6,89% vs C = 12,50%), 
Clostridium (P = 6,85% vs R = 7,03% vs C = 9,85%), Dialister (M = 5,23% vs F = 6,63% vs C 
= 9,35%), Coprococcus (P = 3,54% vs R = 5,35% C = 6,60%) and Lachnospira (P = 1,59% vs 
R = 1,06% vs C = 3,60%), all belonging to Clostridiales order, exhibited the largest, although 
not statistically significant, differences among groups, with the lowest values in CFS/ME 











































(P = 4,52% vs R = 5,14% vs C = 2,14%), Acidaminococcus (P = 1,99% vs R = 0,66% vs C = 
0,11%) and Streptococcus (P = 1,88% vs R = 0,64% vs C = 0,63%) were more frequent in 
CFS/ME patients (not statistically significant). SMB53 (P = 1.15% vs R = 1.86% vs C = 0.05%), 
belonging to Clostridiaceae family, was substantially absent in external controls, although it 
was not statistically significant. 
 
 
Figure 18. Compositions of the intestinal microbiota from CFS patients, relatives and controls at genus level. Only taxa ≥1% 
in at least one sample are shown. 
 
Only 30% of the sample could be classified to species level (Fig. 19). Significant differences 
were observed for species Bacteroides ovatus (P = 0,98% vs R = 1,01% vs C = 0,10%) and 
Bacteroides uniformis (P = 1,23% vs R = 0,91% vs C = 0,14%), which were about 10 times 
more abundant in both CFS/ME patients (p = 0,0001 and p = 0,00005, respectively) and their 
relatives (p = 0,0021 and p = 0,0169, respectively) than in external controls. 
 




























Figure 19. Compositions of the intestinal microbiota from CFS patients, relatives and controls at species level. Only taxa 
≥1% in at least one sample are shown. 
 
Ruminococcus bromii (P = 2,25% vs R = 4,89% vs C = 1,89%) showed a significant increase 
only in patients’ relatives compared to external controls (p = 0,0314).  
Not significant variation in relative abundance were recorded for Roseburia faecis (P = 4,02% 
vs R = 5,72% vs C = 8,41%), Bifidobacterium adolescentis (P = 0,34% vs R = 0,98% vs C = 
1,08%), Bacteroides caccae (P = 1,25% vs R = 0,35% vs C = 0,03%), Faecalibacterium 
prausnitzii (P = 5,01% vs R = 3,91% vs C = 2,31%), Escherichia/Shigella (P = 4,52% vs R = 




























Table 6. Significant differences in bacterial taxa abundances in fecal samples of the three experimental groups. 
Taxon Relative abundance (%) Comparisons producing p value < 0,05 
 PATIENTS RELATIVES CONTROLS (t-test) 
 Phylum  
Bacteroidetes 21,16% 17,40% 10,80% CFS PATIENTS vs CONTROLS (0,0105) 
 Class  
Phylum Bacteroidetes   
Bacteroidia 20,70% 17,12% 8,63% CFS PATIENTS vs CONTROLS (0,0005) 
RELATIVES vs CONTROLS (0,0157) 
Phylum Firmicutes   
Clostridia 64,28% 67,79% 76,96% CFS PATIENTS vs CONTROLS (0,0239) 
 Order  
Phylum: Firmicutes   
Clostridiales 64,26% 67,77% 76,95% CFS PATIENTS vs CONTROLS (0,0238) 
Phylum Bacteroidetes   
Bacteroidales 20,70% 17,12% 8,63% CFS PATIENTS vs CONTROLS (0,0005) 
RELATIVES vs CONTROLS (0,0157) 
 Family  
Phylum: Firmicutes   
Lachnospiraceae 18,07% 20,56% 30,11% CFS PATIENTS vs CONTROLS (0,0345) 
Phylum: Bacteroidetes   
Bacteroidaceae 9,93% 6,59% 1,27% CFS PATIENTS vs CONTROLS (0,0002) 
RELATIVES vs CONTROLS (0,0030) 
Barnesiellaceae 1,71% 1,15% 0,27% CFS PATIENTS vs CONTROLS (0,0005) 
RELATIVES vs CONTROLS (0,0089) 
 Genus  
Phylum: Bacteroidetes                  Fam:              Bacteroidaceae  
Bacteroides 9,93% 6,59% 1,27% CFS PATIENTS vs CONTROLS (0,0002) 
RELATIVES vs CONTROLS (0,0030) 
Phylum: Firmicutes Fam:  Lachnospiraceae   
Anaerostipes 0,18% 0,47% 1,15% CFS PATIENTS vs CONTROLS (0,0220) 
RELATIVES vs CONTROLS (0,0326) 
Phylum: Firmicutes Fam: Veillonellaceae   
Phascolarctobacterium 1,17% 0,76% 0,15% CFS PATIENTS vs CONTROLS (0,0043) 
Phylum: Firmicutes Fam: Ruminococcaceae   
Ruminococcus 6,60% 11,48% 8,21% CFS PATIENTS vs RELATIVES (0,0194) 
  Species   
Phylum: Bacteroidetes Fam: Bacteroidaceae   
Bacteroides uniformis 1,23% 0,91% 0,14% CFS PATIENTS vs CONTROLS (0,00005) 
RELATIVES vs CONTROLS (0,0169) 
Bacteroides ovatus 0,98% 1,01% 0,10% CFS PATIENTS vs CONTROLS (0,0001) 
RELATIVES vs CONTROLS (0,0021) 
Phylum: Firmicutes Fam: Ruminococcaceae   






4.2.2 Oral microbiota diversity 
As for intestinal bacterial communities, α-diversity indices were estimated for each analyzed 
subject. Results showed no differences regarding the total Observed species, the Chao1 and 
Simpson’s diversity indices among CFS/ME patients, their relatives and the external control 





Table 7. OTU-based diversity indexes in salivary samples of the experimental groups of subjects. The table shows the total 
number of OTUs, (b) Chao index and (c) Simpson’s evenness indexes in CFS patients, patients’ relatives and external control 
group respectively. Univariate (ANOVA) test is applied in order to assess significant differences between groups (P < 0.05). 
α-diversity indices P (mean) R (mean) C (mean) 
P- value 
(ANOVA) 
Chao1 9522,56 ± 1521,59 9793,04 ± 2118,92 9347,01 ± 2217,91 0,65 
Sobs 1257,96 ± 97,14 1216,97 ± 91,50 1235,77 ± 139,43 0,37 
Simpson 27,02 ± 11,06 27,36 ± 14,48 28,41 ± 15,27 0,91 
 
 
The distances between the oral microbiome of all participants was assessed by Principal 
Component Analysis (PCA) and by Canonical Correspondence Analysis (CCA). 
PCA results showed a full overlapping of CFS patients, their relatives and external controls 
(Fig. 20).  
 
 
Figure 20. Principal component analysis (PCA) of salivary microbiota compositions in the experimental groups of subjects. 
PCA was performed based on abundance of classified OTUs in CFS patients, patients’ relatives and external healthy controls, 
respectively. The percentages on each axis indicate the variation in the samples. Individuals are labeled according to the three 
groups studied. 
 
Multivariate CCA was carried out on OTUs abundance table in order to evaluate if the microbial 
community distribution across individuals was affected by the health state. In the Fig. 21 CCA 




CFS/ME patients that clustered apart from the other two groups, the model was not significant 
(p = 0,379) and explained only 2,1% of the total variance. 
 
 
Figure 21. Canonical correspondence analysis (CCA) of salivary microbiota compositions in the experimental groups of 
subjects. CCA was performed based on abundance of classified OTUs with frequency >99.9% in CFS patients, patients’ relatives 
and external healthy controls, respectively. The plot shows that the disease status is not a significant source of variability in 
bacterial communities, explaining only 2.1% of the variance in salivary microbiota.  
 
 
When clustering analysis was carried out on OTUs classified at phylum level, a dominance of 
Firmicutes, followed by Actinobacteria, Fusobacteria and Proteobacteria was found (Fig. 22 
A). No grouping was observed, highlighting that the oral microbiomes of the three experimental 








Figure 22. Hierarchical clustering of classified sequences at phylum (A) and family (B) classification levels. The three 
experimental groups are indicated as M (CFS patients), F (patients’ relatives), and C (external healthy controls). Bars of 
different colors indicate the relative percentage of bacterial phyla identified in each salivary sample. Only taxa ≥5% in at least 




At family level, Streptococcaceae was the dominant family, followed by Actinomycetaceae, 
Micrococcaceae and Pausterellaceae (Fig. 22 B). As observed at phylum level, no evident 
clustering was observed. 
In order to detect OTUs whose relative presence was significantly different between groups, 
Metastats analysis was carried out for salivary samples. Six out of the 30 most abundant OTUs 
had relative abundance ≥ 4% and included Streptococcus infantis (OTU00002), Veillonella 
parvula (OTU00003), unclassified TM7-3 (OTU00006) (Fig. 23). The OTUs classified as 
Rothia dentocariosa (OTU00011) and Neisseria subflava (OTU00025) showed significant 
differences among experimental groups. In particular, CFS/ME patients and their relatives had 
a higher relative aboundance of Rothia dentocariosa compared to external controls, while 
Neisseria subflava was significantly lower only in patients’ relatives. 
 
 
Figure 23. Relative abundance of specific OTUs across the three experimental groups. Metastats model was applied on the 




As for fecal samples, the identified OTUs in oral microbiota were classified at different 
taxonomic levels in order to determine the relative abundance of different bacterial taxa 
between samples. The significant differences between experimental groups in the relative 
abundances of oral bacterial taxa are reported in Table 8. The oral cavity bacteria grouped 
within six main bacterial phyla: Firmicutes, Actinobacteria, Proteobacteria, Fusobacteria, 
Bacteroidetes and TM7 (Fig. 24). The predominant phylum Firmicutes (P= 64,20% vs R = 65, 
02% vs C = 64,75%), and Bacteroidetes (P = 4.26% vs R = 4.02% vs C = 5.17%) did not differ 
in terms of relative abundances among the three experimental groups. Actinobacteria (P = 
12,29% vs R = 10,47% vs C = 7,92%) were more abundant in CFS/ME patients (p = 0,01) 
compared to external controls. Furthermore, a decreased proportion of Proteobacteria (P = 
6,97% vs R = 8,77% vs C = 9,85%) and TM7 (P = 3,72% vs R = 4,25% vs C = 4,91%) and a 
higher abundance of Fusobacteria (P = 8,28% vs R = 7,24% vs C = 6,78%) were also detected 
in CFS/ME subjects and in their relatives.  
 
 
Figure 24. Compositions of the oral microbiota from CFS patients, relatives and controls at phylum level.  Only taxa ≥1% in 
at least one sample are shown, while taxa with lower participations were added to the “other” sequence group. 
 
The Firmicutes/Bacteroidetes ratio (P = 15,08 ± 4,06 vs R = 16,18 ± 3,87 vs C = 12,52 ± 3,11) 





































Figure 25. Firmicutes/Bacteroidetes (F/B) ratio in salivary samples across the three experimental groups. Comparison of 
F/B ratio between CFS patients, their relatives and external controls.   
   
A total of 51 orders were identified in the oral microbiota of the three groups. Ten orders were 
found to have a relative aboundance ≥ 1% in at least one sample (Fig. 26).  
 
 
Figure 26. Compositions of the oral microbiota from CFS patients, relatives and controls at order level. Only taxa ≥1% in at 





















































The most interesting variations were observed for Actinomycetales (P = 11,05% vs R = 9,03% 
vs C = 6,38%), significantly higher in CFS/ME patients (p = 0,005) compared to external 
controls, and Pasteurellales (P = 3,58% vs R = 5,28% vs C = 6,12%). Clostridiales (P = 16,09% 
vs R = 18,92% vs C =19,38%) and Flavobacteriales (P = 1,08% vs R = 1,41% vs C = 1,75%) 
resulted less abundant in CFS patients and in their relatives; conversely, Fusobacteriales (P = 
8,28% vs R = 7,24% vs C = 6,78%) was more abundant in CFS/ME patients and their relatives 
(not statistically significant). 
The most aboundant families were Streptococcaceae (P = 40,19% vs R = 38,86% vs C = 
38,30%) and Veillonellaceae, followed by Leptotrichiaceae, Pasteurellaceae, Gemellaceae, 
Actinomycetaceae, Neisseriaceae, Carnobacteriaceae, Fusobacteriaceae and 
Flavobacteriaceae. (Fig. 27).  
 
 
Figure 27. Compositions of the oral microbiota from CFS patients, relatives and controls at family level. Only taxa ≥1% in at 
least one sample are shown, while taxa with lower participations were added to the “other” sequence group. 
 
 
The greatest variations were observed for two families belonging to Actinomycetales order, 











































patients (p = 0.014), and Actinomycetaceae (P = 3,37% vs R = 2,39% vs C = 2,22%) that were 
more abundant in CFS/ME patients. Pasteurellaceae (P = 3,58% vs R = 5,28% vs C = 6,12%), 
Veillonellaceae (P = 12,59% vs R = 16,25% vs C = 15,45%) and Flavobacteriaceae (P = 1,04% 
vs R = 1,39% vs C = 1,72%) were less frequent in CFS/ME patients, while the opposite was 
recorded for Leptotrichiaceae (P = 6,40% vs R = 5,35% vs C = 4,86%) and Carnobacteriaceae 
(P= 2,27% vs R = 1,89% vs C = 1,70%). 
Streptococcus, Veillonella, Rothia, Leptotrichia, Haemophilus, Gemella, Actinomyces, 
Granulicatella, Neisseria, Fusobacterium, Capnocytophaga and Porphyromonas were the 
most representative genera, with a relative abundance greater than 1% (Fig. 28). In particular, 
CFS/ME patients exhibited differences in the relative abundances of members belonging to 
Actinomycetales order.  
 
 
Figure 28. Compositions of the oral microbiota from CFS patients, relatives and controls at genus level. Only taxa ≥1% in at 
least one sample are shown. 
   
The genus Rothia (P = 7,44% vs R= 6,38% vs C = 3,97%) was significantly more abundant in 
CFS/ME patients (p = 0.014). Actinomyces (P = 3,36% vs R = 2,38% vs C = 2,21%), 
Leptotrichia (P = 6,32% vs R = 5,35% vs C = 4,44%) and Granulicatella (P = 2,27% vs R = 
1,89% vs C = 1,70%) showed higher abundance in CFS/ME patients, while the opposite was 





















recorded for Haemophilus (P = 3,47% vs R = 5,08% vs C = 5,69%), Capnocytophaga (P = 
1,04% vs R = 1,39% vs C = 1,72%) and Veillonella (P = 11,39% vs R = 14,42% vs C = 13,55%). 
At species level (Fig. 29), the most evident differences were observed for the species Rothia 
mucilaginosa (P = 5,74% vs R = 4,37% vs C = 3,18%) and Rothia dentocariosa (P = 1,03% vs 
R = 1,53% vs C = 0,50%), both members belonging to Actinobacteria phylum, with the latter 
significantly increased both in CFS/ME patients (p = 0,01) and in their relatives (p = 0.010) 
compared to external control group. 
Streptococcus infantis (P = 27,63% vs R = 26,39% C =26,38%) was the most abundant species 
in all groups. Neisseria subflava (P = 1,92% vs R = 1,22% vs C = 2,11%), a member belonging 
to Proteobacteria, was significantly less abundant only in patients’ relatives (p = 0,028), while 
no substantial differences were observed between CFS/ME patients and external controls. 
Haemophilus parainfluenzae (P = 3,41% vs R = 4,23% vs C = 5,45%), Streptococcus salivarius 
(P = 2,48% vs R = 3,14% vs C = 4,24%) and Veillonella dispar (P = 6,20% vs R = 9,38% vs C 




Figure 29. Compositions of the oral microbiota from CFS patients, relatives and controls at species level. Only taxa ≥1% in 
at least one sample are shown. 
 


















Table 8. Significant differences in bacterial taxa abundances in salivary samples of the three experimental groups. 
Taxon 
 
Relative abundance (%) Comparisons producing  
p value < 0,05 (t test) 
 PATIENTS RELATIVES CONTROLS  
 Phylum  
Actinobacteria 12,29% 10,47% 7,92% CFS PATIENTS vs CONTROLS (0,014) 
 Order  
Actinomycetales 11,05% 9,03% 6,38% CFS PATIENTS vs CONTROLS (0,005) 
  Family  
Phylum: Actinobacteria     
Micrococcaceae 7,44% 6,39% 3,98% CFS PATIENTS vs CONTROLS (0,014) 
 Genus  
Phylum: Actinobacteria Fam: Micrococcaceae   
Rothia 7,44% 6,38% 3,97% CFS PATIENTS vs CONTROLS (0,014) 
            Species   
Phylum: Actinobacteria Fam: Micrococcaceae   
Rothia dentocariosa 1,03% 1,53% 0,50% CFS PATIENTS vs CONTROLS (0,034) 
RELATIVES vs CONTROLS (0,010) 
Phylum: Proteobacteria Fam: Neisseriaceae   




























4.3 UPLC-MS analysis  
Based on the results of the metagenomic analysis of intestinal microbiota in CFS/ME patients, 
to evaluate whether the metabolic profile of CFS/ME patients differed from those of their 
relatives and controls, a pilot study was conducted on the fecal samples of 5 CFS/ME patients 
(M12-M2-M10-M7-M24) which belonged to a same cluster at family level. Five relatives of 
these patients and five external controls were also selected. The UPLC-MS analysis was carried 
out according to a untarget approach and resulted in 4848 extracted features. These features, 
with their relative retention time and single mass spectrum, were normalized for the baseline 
and the percentile shift at 75%, and filtered in order to eliminate features that were potentially 
not interesting for analysis. 
PCA was applied to explore the distribution of the samples and evaluate the presence of clusters 




Figure 30. PCA (unsupervised) model for the classification of the three experimental sub-groups. In red are represented CFS 
patients, in brown the relatives and in blue the controls. 
 
 
The three groups of subjects under investigation were distinct, with a total explained variability 
> 65%, although a clear separation was not observed and except for one sample. 
Partial Least Square-Discriminant Analysis (PLS-DA) showed a more evident separation 






Figure 31. PLS-DA (supervised) model through multivariate statistical analysis with the representation of the two principal 
components for the classification of the three experimental groups. In red are represented CFS patients, in brown the 
relatives and in blue the controls. 
 
The filtered data set was used for an Orthogonal Latent Structure-Discriminant Analysis 
(OPLS-DA) classification model using Pareto scaling. The application of the OPLS-DA 




Figure 32. OPLS-DA (supervised) model for the classification of the three experimental sub-groups. R2 indicates the % 




The permutation test was performed in order to show that the differences between the groups, 
highlighted by the OPLS-DA analysis, are not the result of random associations between 
features. The results showed that the model is not random (Q2<0, Fig. 33). 
 
 
Figure 33. Permutation test for the three experimental sub-groups. R2 indicates the % variability explained by the model; Q2 
estimates the predictive power of the model. 
 
 
Using MS-DIAL software, 1403 single-mass compounds were identified by comparing the 
retention time and mass spectrum of the features to those reported in MoNA database. Of these, 
125 metabolites also had a MS/MS spectrum, but only 7 matched 100% after alignment. An in 
silico prediction was performed aligning the characteristics of retention time and mass spectrum 
of the features to those in other databases (i.e Human Metabolome Database) and determining 
an affinity score. 
Using the MS Finder software, a multivariate OPLS-DA analysis was performed resulting in a 







Figure 34. The score (A) and loading (B) plots from OPLS-DA model. In the loading plot, the variables which contributes the 
most to group discrimination are shown in blue. 
 
Results clearly showed that the metabolic profile of CFS/ME patients is quite different from 
that of their relatives and external controls. In the score plot, biological variability explained 
the differences observed between CFS/ME patients and healthy subjects (relatives and external 
controls), while orthogonal variability explained the differences between patients' relatives and 
external controls. Interestingly, the patients’ relatives and controls tended to cluster together, 
showing that their metabolic profiles were similar.  
VIP (Variable Importance in Projection) scores, a measure of a variable’s contribution to the 




showed a VIP score greater than 1 and represented the most contributory variables in group 
discrimination in the OPLS-DA model. 
Several compounds derived from bacterial metabolism, such as SCFAs (acetate, propionate and 
butyrate), branched-chain fatty acids (BCFA: isobutyrate, valerate, and isovalerate), indole 
derivatives, choline metabolites, mono- and polyamines, amino acids, peptides, vitamins and 
bile acid metabolites, contributed to the metabolic differentiation between the three 
experimental groups (Table 9).  
 
Table 9. Annotated metabolites derived from bacterial metabolism. Metabolites which differed between CFS patients (P), 
their relatives (R) and external controls (C) and with VIP (Variable Importance in Projection) scores > 1 as assessed by OPLS-
DA model. Fold changes of metabolites were the ratio of the average MS ion intensities (peak areas) in CFS patients, their 
relatives and external controls.  






p value F-change 
R/C 
p value VIP 
score 
 Butyric acid        
3673 -4-oxobutanoic acid 9,1 545,3 12,8 0,28 4,2 1,0 2,3 
1300 -butanoic acid 2,6 269,2 0,0 0,40 0,1 0,55 1,6 
463  4-acetamidobutanoate 1,8 146,1 3,2 0,83 1,0 1,0 1,3 
3730 -2-ethylbutanoate 13,8 550,3 4,4 0,20 1,0 0,38 1,2 
3152 -4-oxobutanoic acid 10,8 483,3 2,8 0,20 1,0 0,38 1,2 
3429 -butanoate 12,3 517,1 2,9 0,18 1,0 0,22 1,2 
2825 -2-methylidenebutanoate 9,7 444,2 2,8 1,0 1,0 1,0 1,2 
2680 -4-oxobutanoic acid 9,7 426,3 0,5 1,0 1,7 1,0 1,1 
3419 -butanoic acid 5,1 516,2 0,1 1,0 0,3 1,0 1,1 
 Propionic acid        
5248  -propanoic acid 11,3 807,6 0,4 0,11 0,9 1,0 1,6 
3444  -propanoic acid 12,4 519,1 2,8 0,52 1,0 1,0 1,3 
4038  -propanoic acid 12,9 582,4 2,8 0,18 1,0 0,22 1,2 
4148  -2-methylpropanoic acid 12,4 591,3 0,2 0,64 0,6 1,0 1,2 
5107  -propanoic acid 13,0 738,2 8,6 0,30 1,0 0,51 1,1 
3738  -3-oxopropanoic acid 11,4 551,1 987,7 1,0 1,0 1,0 1,0 
3252  -2-methylpropanoate 7,2 496,3 1,0 1,0 7,7 1,0 1,0 
 Acetic acid        
3002  -acetate 8,7 466,3 5,0 1,0 0,0 1,0 2,0 
1520  -acetate 5,6 295,1 27,4 0,26 12,2 0,62 1,5 
3615  -acetate 8,9 539,2 3,7 0,86 0,3 1,0 1,4 
829  -acetic acid 2,9 192,1 2,8 1,0 2,8 0,85 1,4 
4456  -2-phenylacetate 14,6 616,2 11,4 1,0 1,0 1,0 1,2 
3508  -acetate 11,3 527,3 2,8 1,0 1,0 1,0 1,2 
5084  -acetate 11,4 728,5 2,8 1,0 1,0 1,0 1,1 
2344  -acetate 11,2 375,3 0,4 0,10 1,1 1,0 1,1 
3302  -diacetate 8,6 501,2 2,8 0,40 1,0 0,14 1,0 
 Isobutyric acid        
891 -2-methylpropanoic acid 2,5 204,1 0,8 1,0 0,7 1,0 1,1 




1716  -3-methylpentanoate 8,3 310,2 4,6 0,13 3,2 0,82 2,2 
2713  -3-methylpentanoic acid 12,6 429,3 0,1 0,39 1,5 1,0 1,1 
 Isovaleric acid        
3445  -3-methylbutanoic acid 9,6 519,3 2,8 1,0 1,0 1,0 1,2 
 Mono- and polyamines        
539   Dopamine 1,8 154 1,8 0,84 0,7 1,0 2,9 
540   N-Acetylhistamine 1,8 154,1 0,0 0,64 0,0 0,68 2,0 
809   N8-Acetylspermidine 1,6 188,2 0,2 0,21 0,2 0,28 1,5 
356   Phenylethanolamine 2,1 138,1 1,2 1,0 0,7 1,0 1,5 
2886  -3-phosphoethanolamine 13,8 454,3 0,0 0,42 0,2 0,75 1,3 
469   Spermidine 1,6 146,2 0,7 1,0 0,9 1,0 1,3 
678   3-Methoxytyramine 2,3 168,1 3,0 1,0 1,0 1,0 1,2 
630   N-acetyl-2-phenylethylamine 2,8 164,1 0,9 1,0 0,1 0,65 1,0 
299   N-Acetylputrescine 1,6 131,0 2,8 1,0 1,0 1,0 1,2 
 Indole derivatives        
3012  -isoindole-6'-one 9,2 468,2 6,0 0,10 1,0 0,40 2,1 
3062  -isoindole-1,15-dione 7,0 472,2 0,1 0,42 1,0 1,0 1,9 
2847  -isoindole-6'-one 16,8 447,3 8,8 0,53 3,0 1,0 1,4 
4398  -indole-3-carboxylic acid 14,6 613,2 3,3 0,35 1,0 0,29 1,3 
2754  -indole-2,5(3H)-dione 2,0 434,2 0,0 0,34 0,2 0,61 1,3 
946  -indole 3,3 213,1 2,8 1,0 1,0 1,0 1,2 
1567  -indole-1,4(3H,5aH)-dione 5,9 298,2 2,8 1,0 1,0 0,45 1,2 
798  -indole 3,5 187,1 2,8 0,33 1,0 0,76 1,2 
2792  -isoindole-1,15(2H)-dione 13,1 440,3 0,3 0,35 0,4 0,37 1,2 
2999  -isoindole-1,15(2H)-dione 9,0 466,3 2,8 0,30 1,0 0,51 1,1 
2640  -isoindole-1,15(2H)-dione 8,5 420,3 2,8 1,0 1,0 1,0 1,1 
2763  -isoindole-2,16-dione 8,7 435,3 2,8 0,61 1,0 0,51 1,1 
288   Indole-3-carbinol 2,6 130,1 2,8 1,0 1,0 1,0 1,1 
3000  -isoindole-1,16(2H)-dione 6,8 466,3 0,1 1,0 0,2 1,0 1,1 
600   N-Acetylindole 2,3 160,1 0,3 1,0 0,7 1,0 1,0 
 Choline metabolites        
917   Benzoylcholine 2,8 208,1 4,8 0,41 1,7 1,0 1,6 
464   Acetylcholine 2,7 146,1 0,1 0,18 0,1 0,22 1,2 
136   Betaine 1,8 118,1 0,1 1,0 0,8 1,0 1,1 
 Vitamins        
985   Pantothenic acid (B5) 2,0 220,1 1,5 1,0 3,4 1,0 2,0 
 Bile acid metabolites        
2604  Alpha-hydroxydeoxycholic 
acid 
11,2 415,3 0,1 0,36 2,6 1,0 1,4 
 Amino acids        
812 N-alpha-acetyl-L-lysine 1,9 189,1 0,2 0,38 0,5 1,0 2,1 
134 Norvaline 13,1 118,1 0,3 1,0 3,2 0,64 1,3 
651 Phenylalanine 2,0 166,1 0,1 0,2 1,1 1,0 1,3 
139 beta-N-Methylaminoalanine 3,7 119,1 2,9 0,18 1,0 0,22 1,2 
491 L-Glutamate 2,1 148,1 0,2 0,8 0,6 1,0 1,0 
 Peptides        
547 Cyclo-prolylglycine 1,9 155,1 0,8 1,0 0,8 1,0 1,9 





An overall increase of SCFAs derivatives was observed in fecal samples of CFS/ME patients, 
while no difference was recorded between their relatives and external controls, except for some 
metabolites (not statistically significant). Interestingly, -3-oxopropanoic acid (ID3738) showed 
a very high level in CFS/ME patients compared to external controls, while their relatives did 
not differ. Moreover, CFS/ME patients and their relatives reported high levels of -4 oxobutanoic 
acid (ID3673), acetate (ID1520) and -3-methylpentanoate (ID1716). An increase of -3-
methylpentanoate (a valerate derivative) was observed both in CFS/ME patients and in their 
relatives compared to controls, while no difference in isobutyrate level was observed among 
the three populations. In addition, CFS/ME patients showed high level of isovalerate, not 
observed in their relatives. All amino acids levels (except for beta-N-Methylaminoalanine) were 
slightly decreased in CFS/ME patients compared to external controls. Three biogenic amines 
derived from amino acids metabolism, such as dopamine (ID539), -3-methoxytyramine 
(ID678), N-acetilputrescine (ID299), and several indole derivatives were increased only in 

























5. DISCUSSION  
 
In recent years, several studies have established the important role played by the microbiota in 
human health and its implication in disease development. (Robinson et al., 2010; Bassis et al., 
2013). In a state of equilibrium, which can be identified with the state of health, there is a 
functional cooperation between the host and colonizers that enhances nutrient metabolism, the 
synthesis of vitamins, containment of pathogen proliferation and development and maturation 
of the immune system (Nicholson et al., 2012; Kau et al., 2011). The oral and intestinal 
microbiota represent the most dominant microbial communities in humans, and it is well known 
that both are able to display signatures associated with pathologies (Abe et al., 2018; Shengtao 
et al., 2019).  
As concerns the CFS/ME syndrome, which is characterized by chronic fatigue and 
multisystemic alterations, till now the relationship between the bacterial composition and 
pathogenesis of CFS/ME has not been fully demonstrated, although previous studies reported 
alterations of intestinal and oral microbiota (Fremont et al., 2012; Shukla et al., 2015; Giloteaux 
et al., 2016; Nagy-Szakal et al., 2017; Wang et al., 2018). Some features of this syndrome, such 
as the “relapsing-remitting” symptoms and persistent immune activation, suggest a similarity 
with autoimmune conditions. Another feature that deserves to be emphasized, is the cognitive 
impairment frequently observed in CFS/ME patients (Chen, et al., 2008). As a consequence, 
the possible disturbance of the so-called microbiota-gut-brain axis needs to be further 
investigated. 
The results of the present study showed significant variations in both the intestinal and oral 
bacterial composition between CFS/ME patients, their relatives and external controls. However, 
some differences, although not statistically significant, deserve to be highlighted.  
First of all, the intestinal and oral microbiota of CFS/ME patients exhibited modifications in 
the bacterial composition compared to healthy controls, due to changes in the relative 
abundances of several bacterial taxa. Interestingly, the relatives, in the most cases, showed 
intermediate prevalence values.  
β-diversity analyses showed a reduced inter-individual variability between CFS/ME patients 
and healthy subjects for both the salivary and fecal microbiota. 
 
Considering the fecal microbiota, the analysis at taxon level showed a reduction of Firmicutes 




comparison with the non-CFS/ME groups. The prevalence of these phyla showed intermediate 
values in patients’ relatives, suggesting an environmental influence. A further evidence of 
environmental conditioning is the observation of a similar increased prevalence of 
Proteobacteria in patients and in their relatives. Considering the F/B ratio, a progressive 
decrease of this index was observed in CFS/ME patients and in their relatives, with the highest 
value in external controls and the lowest in patients.  
These results agree with those of previous studies, reporting that the intestinal microbiome in 
CFS/ME patients is characterized by less members belonging to Firmicutes phylum and more 
Bacteroidetes (Fremont et al., 2012; Shukla et al., 2015; Giloteaux et al., 2016). A similar 
pattern has been observed also for the fecal microbiome of patients with Alzheimer’s disease 
(Vogt et al., 2017). The microbiome plays an important role in gut-brain communication 
through the gut-brain axis (Zhul et al., 2017), synthesizing a large number of chemical 
mediators (including neurotransmitters such as dopamine, serotonin and GABA), which, being 
released into the bloodstream, can reach distant sites, such as the brain, exerting positive or 
negative effects on the host health (Clarke et al., 2014). Changes in the composition and 
abundance of intestinal microorganisms may also affect the host response to stress, through the 
modification of the intestinal-brain physiology (Cryan et al., 2012), affecting cognitive and 
behavioral functions (Zhul et al., 2017). 
The shift in Firmicutes/Bacteroidetes ratio observed in the present study has been previously 
described in various autoimmune conditions, such as Chron’s disease (Manichanh et al., 2006) 
and Systemic Lupus Erythematous (Hevia et al., 2014), and in diabetes type 2 (Larsen et al., 
2010).  Conversely, an increase in F/B ratio has been observed in relation to obesity (Koliada 
et al., 2017; Ismail et al., 2011). 
In our study, the reduction of Firmicutes and the increased proportion of Bacteroidetes observed 
in CFS/ME patients and in their relatives was mainly ascribed to members of Clostridiales and 
Bacteroidales, respectively. Within Clostridiales, several families declined, with 
Lachnospiraceae showing the greatest decrease. Lachnospiraceae are abundant in the 
gastrointestinal tract of humans (Gosalbes et al., 2011; Rinninella et al., 2019). All members 
belonging to this family are strictly anaerobic and spore-forming bacteria, and several species 
are important butyrate producers (Duncan et al., 2002). The capability of producing butyric 
acid and its important role for both microbial and host epithelial cell growth link the members 
of this family to both obesity (Duncan et al., 2008; Turnbaugh et al., 2008) and protection from 
colon cancer in humans (Mandal et al., 2001). A low abundance of Lachnospiraceae has been 
observed in pediatric patients with ulcerative colitis and Chron’s disease (Maukonen et al., 




also under represented in the gut of adult IBD patients (Frank et al., 2007). Also patients with 
non-alcoholic fatty liver disease (NAFLD) and with liver cirrhosis show a significant reduction 
in Lachnospiraceae abundance (Wang et al., 2016; Chen et al., 2011). A previous study, carried 
out on rats with stressed-induced visceral hypersensitivity, reported a decreased abundance of 
several OTUs related to butyrate-producing Lachnospiraceae and a reduced representation of 
pathways involved in the metabolism of butyrate. 
The decrease in Lachnospiraceae that we recorded involved the genera Roseburia, 
Coprococcus, Lachnospira and Anaerostipes. All these genera are dominant in the healthy 
human gut and most of them are butyrate producers; butyric acid is a SCFA which production 
not only represents an important energy source for other microbes and for the host’s 
enterocytes, but also contributes to the maintenance of the intestinal barrier and protection of 
the gut epithelium against inflammation (Venegas et al., 2019). In particular, we observed a 
significant reduction of Anaerostipes both in CFS patients and in their relatives. Anaerostipes 
converts lactate to butyrate and has been found to be reduced also in smoking IBD patients 
(Morgan et al., 2012).  
Similarly, Roseburia showed a 50% decrease in CFS/ME patients, although this result was not 
statistically significant. This finding agrees with a previous pubblished study on CFS/ME 
patients from northern Europe (Fremont et al., 2012). Roseburia is the major butyrate producing 
genus in the human gut and contributes to the health of colon epithelium.   
A decrease in the abundance of this genus has been reported also in inflammatory diseases, 
such as IBD (Machiels et al., 2014; Takahashi et al., 2016), and in early onset reumatoid 
arthritis (Vaahtovuo et al., 2008). Lachnospira has been reported to decline also for other 
pathological conditions, such as asthma (Stiemsma et al., 2016) and Chron’s disease (Wang et 
al., 2018) in pediatric patients. 
Furthermore, we observed that the fecal microbiota of CFS/ME patients was enriched in 
Streptococcus, a group of D-lactic acid producing bacteria previously observed more abundant 
in a cohort of CFS/ME patients by Sheedy et al. (2009). 
Within Bacteroidales we detected other interesting modifications. A significant increase in 
Bacteroidaceae and Barnesiellaceae, particularly Bacteroides and Barnesiella, was observed 
both in CFS/ME patients and their relatives. Bacteroides is the predominant genus within the 
lower human intestinal tract. All members belonging to this genus are Gram-negative, obligate 
anaerobic and non-spore-forming species. These bacteria play a fundamental role in the 
processing of complex molecules in the host intestine, particularly in carbohydrate 
fermentation. This activity results in the production of SCFA, mainly propionate and acetate, 




butyrate-producing bacteria normally present in the human gut. This species exhibits expanded 
greater glycolytic capability with respect to other Bacteroides species and is able to use dietary 
or endogenous glycans to produce butyrate (Benítez-Páez et al., 2017). The oral administration 
of Bacteroides uniformis CECT 7771 was found to ameliorate metabolic and immunological 
dysfunction in mice with high-fat-diet induced obesity (Gauffin et al., 2012). 
Studies on the modification of bacterial composition in relation to diet showed that fecal 
communities cluster into three enterotypes that are strongly associated with long-term diets. 
Particularly, Bacteroides are predominant in subjects who follow a typical western, rich in 
protein and lipids diet, while Prevotella is the predominant genus in humans with a 
carbohydrate rich diet, especially fibers, (Wu et al., 2011). Although Bacteroides species are 
normally commensals in the human gut flora, some of them are opportunistic pathogens that 
have been found in most infections of the peritoneal cavity, particularly appendicitis through 
abscess formation (Bennion et al., 1990), and can cause anaerobic bacteremia (Merchan et al., 
2016).  
Bacteroides possess virulence factors involved in the adherence to tissues, protection from the 
host’s immune response and consequent destruction of tissues. The polysaccharide capsule and 
lipopolysachcarides (LPS) of some Bacteroides species protect them from the host immune 
response (Coyne et al., 2000). LPS, also known as endotoxin, can induce a high inflammatory 
response when enter into the bloodstream. (Zhang et al., 2009). LPS are able to affect intestinal 
homeostasis by either changing the permeability of or triggering immune reaction inside the 
intestinal mucosa. High levels of some markers of microbial translocation, including LPS, were 
detected in the bloodstream of subjects with CFS/ME (Giloteaux et al., 2016).  
Among other virulence factors, the enterotoxins and histolytic enzymes found in Bacteroides 
fragilis, namely BFT, hyaluronidase and chondroitin sulfatase, can cause tight junction 
destruction in gut epithelium, resulting in a “leaky gut” and tissue damage (Wu et al., 1998; 
Riepe et al., 1980). Moreover, it has been reported that persistent infection of mice with 
Bacteroides fragilis cause chronic colitis (Rhee et al., 2009). 
A proteomic analysis performed on individuals affected by Chron’s disease has revealed an 
over-representation of many proteins, largely derived from Bacteroides species, which allow 
these opportunistic pathogens to break the intestinal barrier and invade the mucosa (Juste et al., 
2014).  
In our study we found a significantly increased prevalence of Bacteroides vulgatus and 
unclassified Bacteroides in CFS patients and their relatives. These results are not totally in 
agreement with the findings of a previous study, which reported a reduction in Bacteroides 




mainly composed by patients without IBS, nonetheless in a preliminary evaluation we did not 
observe any difference between CFS patients with and without IBS. An increase in Bacteroides 
vulgatus abundance was also reported in the gut of subjects with Type 1 diabetes (Higuchi et 
al., 2018) and in children with autism spectrum disorder (Finegold et al., 2010), both 
autoimmune conditions. 
Barnesiella is a genus belonging to Porphyromonadaceae, that is usually found at low levels 
in the human gut, less than 1% of the total gut bacteria in healthy individuals, and the role of 
which in health is still unclear (Wylie et al., 2012). Barnesiella produces butyric and iso-butyric 
acids. This genus is a poorly characterized and to date no literature data are available on its 
direct involvement in pathological conditions. However, Barnesiella may regulate the microbial 
composition by inhibiting the propagation of Clostridia and other potentially harmful microbes 
(Ubeda et al., 2013). Accordingly, an increase in Bacteroides, Barnesiella and Alistipes has 
been reported for patients affected by Clostridium difficile infection (CDI), paralleled by a 
decrease in several bacterial groups of the phylum Firmicutes (Milani et al., 2016). 
In addition to the observed decrease in Lachnospiraceae and increase in Bacteroides and 
Barnesiella genera, in CFS patients we recorded also a large decrease in the genera Clostridium, 
Ruminococcus and Dialister and a higher prevalence of Acidamminococcus and 
Phascolarctobacterium. These results are similar to those reported in a study carried out on 
individuals with Alzheimer’s disease (Vogt et al., 2017). Phascolarctobacterium is an 
acetate/propionate-producer abundant in the human gut. In our study, its increase may be related 
to dietary habits. Indeed, a previous study demonstrated that rats fed with fat rich diets showed 
a higher amount of SCFAs producers, including Phascolarctobacterium faecium (Lecomte et 
al., 2015). Moreover, Phascolarctobacterium spp. are able to use the succinate produced by 
other bacteria (Dot et al, 1993), such as Bacteroides and Parabacteroides, which abundances 
are increased by fat rich diets and are positively correlated with body weight (Lecomte et al., 
2015).  
Another bacterium able to produce acetate and propionate is Dialister invisus (Downes et al., 
2003), which lacks in patients with Chron’s disease (Joossens et al., 2011).  
The abundance of several Ruminococcus species was found to be lower in fecal samples of 
Chron’s disease patients than in healthy control subjects (Kang et al., 2010). Ruminococcus 
albus produces acetate by degrading the cellulose introduced with food (Miller et al., 1995). 
Acetate is the most abundant SCFAs in the colon and plays a major role in the production of 
butyrate, which represent the first energy source for enterocytes (Louis et al., 2010).  
The decrease in Bifidobacterium that we recorded in the fecal samples of CFS/ME patients, was 




al., 2016). A significant decrease of Bifidobacterium was reported also in other pathological 
conditions, such as IBS (Tana et al., 2010), IBD (Swidsinski et al., 2002) and type II diabetes 
(Wu et al., 2010). Bifidobacteria are a group of lactic acid-producing bacteria known to be 
beneficial in healthy subjects and that are widely used as probiotics [Furrie et al., 2005]. 
Treatment with Bifidobacterium infantis has been reported to lower CRP levels in CFS/ME 
patients (Groeger et al., 2013) 
In the present study CFS/ME patients showed a higher abundance of Enterobacter, belonging 
to the Proteobacteria phylum, and in particular an increase of Escherichia/Shigella species. 
Despite these differences were not statistically significant, they are worthy of being 
emphasized. Proteobacteria includes six classes of bacteria, out of which 
Gammaproteobacteria are the most numerous and include several pathogenic bacteria such as 
Escherichia coli and Shigella sp. Escherichia and Shigella are more abundant in the intestinal 
mucosa and stool of IBD (Petersen et al., 2015) and Chron’s disease patients (Kang et al., 2010; 
Lapaquette et al., 2010). In particular, adherent-invasive Escherichia coli (AIEC) has been 
found in IBD patients (Darfeuille-Michaud et al., 2004); AIEC can invade the intestinal 
epithelium, causing tissue damage and the outbreak of inflammatory processes which induce a 
preferential environment for other potential pathogenic bacteria. 
 
The analysis of salivary microbiota revealed a greater species richness, than that observed in 
feces. The dominant phyla were, in order of abundance, Firmicutes, Actinobacteria, 
Proteobacteria, Fusobacteria, Bacteroidetes and TM7. Differently from the fecal microbiota, 
the phyla Acidobacteria, Fibrobacteres and Gemmatimonadales were not detected, while TM7 
and Fusobacteria were found only in saliva. The comparison among CFS patients, their 
relatives and external controls pointed out major differences for Actinobacteria, which 
significantly increased in CFS patients.  
The Firmicutes/Bacteroidetes ratio slightly increased in the oral microbiome of both CFS/ME 
patients and their relatives, with similar values. The increased F/B ratio observed was due to a 
slight decrease in Bacteroidetes in CFS/ME patients and in their relatives, while Firmicutes did 
not differ across the three experimental groups. In addition, Fusobacteria and Proteabacteria 
showed either a progressive increase or decrease, respectively. Similar changes in the relative 
abundances of Fusobacteria and Proteobacteria were found in a recent study on the oral 
microbiota of CFS/ME patients (Wang T et al., 2018). 
The increased abundance of Actinobacteria that we observed in CFS/ME patients and, to a 
minor extent, in their relatives was associated with a higher prevalence of Actinomycetales. 




sp., only in CFS/ME patients, while Actinomycetaceae resulted slightly more abundant both in 
patients and their relatives, although the difference was not statistically significant.  
Rothia is a Gram-positive and aerobic bacterial genus that normally occurs in the mouth and 
respiratory tract. It ferments carbohydrates and is the major producer of lactic acid. We 
identified two pathogenic species belonging: Rothia dentocariosa and Rothia mucilaginosa. 
The statistical significance was obtained only for R. dentocariosa. 
R. dentocariosa was isolated from dental caries and is responsible of endocarditis in subjects 
with heart valve disorders (Ricaurte et al., 2001). This species is implicated in peridontal 
disease, which may represent the first step in the infection of other body sites. Indeed, some 
findings indicate that oral bacteria are able to translocate into the bloodstream reaching various 
tissues, such as the brain (Singhrao et al., 2015) and coronary arteries (Mougeot et al., 2017). 
Several studies reported that R. dentocariosa is involved in the infection of lung, tonsils, 
peritoneum and brain (Ohashi et al., 2005; Morris et al., 2004; Ricaurte et al., 2001).  
A previous study reported that R. dentocariosa was responsable for septic arthritis in a patient 
with rheumatoid arthritis (Favero et al., 2009). A case of R. dentocariosa bacteremia has been 
described in a patient with ulcerative colitis (Yeung et al., 2014).  
Even if the increase in abundance of Anctinomycetaceae was not significant, it is worth noting 
that Actinomyces spp. are opportunistic pathogens that colonize the upper respiratory tract, 
gastrointestinal tract and female genital apparatus (Evaldson et al., 1982). Some species are 
responsable of a chronic disease called actinomycosis, a bacterial infection of several body sites 
characterized by chronic granulomatous lesions and abscess formation (Vaulor et al., 2014). 
Actinomyces can also cause bacteremia. Actinomyces species are frequently detected in the 
bloodstream of patients, due to increased permeability of the oral mucosa (Lockhart et al., 
2009).  
Furthermore, in the salivary microbiota of CFS/ME patients we observed slight differences in 
the abundance of several other genera, such as Haemophilus, Leptotrichia and Veillonella. 
Haemophilus, showed the highest abundance values in external controls and the lowest in 
CFS/ME patients. Veillonella decreased only in CFS patients. The relative abundance of these 
two genera has been found altered in the oral microbiome of individuals positive to the human 
immunodeficency virus (Kistler et al., 2015) and in oral lesions (Koopman et al., 2015). 
Leptotrichia increased in CFS/ME patients and, to a minor extent, in their relatives compared 
to external controls. Species belonging to this genus are opportunistic pathogens and are 
associated with oral cavity abscesses and periodontal diseases (Sassone et al., 2007). In 
addition, in immunocompromised subjects Leptotrichia species are involved in severe 




The recorded changes in the prevalence of Haemophilus, Veillonella and Leptotrichia agree 
with the findings of a recent study carried out on Chinese CFS/ME patients (Wang et al., 2018).  
 
The fecal metabolic profile of CFS/ME patients, as assessed by UPLC-MS analysis, resulted to 
be different compared to that of their relatives and external controls, although the differences 
were not statistically significant. Interestingly, supervised PLS-DA showed that patients’ 
relatives exhibited a metabolic profile more similar to that of external controls compared to 
CFS/ME patients.  
Several products of bacterial metabolism contributed to the metabolic differentiation of the 
three groups. An overall increase of SCFAs derivatives, although no statistically significant, 
was observed in the CFS/ME cohort. Acetate, butyrate and propionate are the main SCFAs of 
the gut and it is wellknown that they are essential for its health (Wong et al., 2006). Microbial 
SCFAs are an important energy source for intestinal cells and affect the energy metabolism of 
the host through their incorporation into lipids in adipocytes and oxidation in muscle cells and 
hepatocytes to produce glucose and glycogen (Canfora et al., 2015; den Besten et al., 2013). In 
our study we found an increase of -3-methylpentanoate (a valerate derivative) both in CFS/ME 
patients and in their relatives compared to controls, while no difference in isobutyrate level was 
observed among the three populations. In addition, CFS/ME patients showed high level of 
isovalerate, not observed in their relatives. Valerate is a SCFA produced in small quantities by 
the fermentation of carbohydrates or peptides (Bourriaud et al., 2005).  
The metabolites we observed in CFS/ME suggest an increase in the fermentation process that 
may depend on changes in the composition of the intestinal microbiota, a slowed gut transit or 
a high pH. Previous studies reported that the fementation process of lactate and amino acids to 
SCFA in the gut increases under alkaline conditions (Belenguer et al., 2007).  
In the present study, all amino acids levels (except for beta-N-Methylaminoalanine) slightly 
decreased in CFS/ME patients compared to external controls.  
Beta-N-Methylaminoalanine (L-BMAA) is a non-proteinogenic amino acid produced by 
Cyanobacteria. It is a neurotoxin that has been postulated as a possible cause of 
neurodegenerative disorders, such as Alzheimer's disease, amyotrophic lateral sclerosis, and 
Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex (ALS-PDC) syndrome of 
Guam (Bradley et al, 2009). The observed increase in L-BMAA is an interesting outcome of 
this study, because many CFS/ME patients frequently report neuromotor and cognitive 




Also microbial data appear consistent with an increased fermentation in CFS/ME patients, as 
we observed an increase of several acetate/propionate-producing species (i.e Bacteroides, 
Phascolarctobacterium).   
Previous studies on CFS/ME patients have reported an increased production of fecal SCFAs 
derived from microbial fermentation, proposing a possible association with deleterious effects 
on the host energy metabolism (Armstrong et al., 2016).  
Although SCFAs have beneficial effects on human health, their increase has been observed in 
autism spectrum disorder (ASD) (Wang et al., 2012). Indeed, the administration of propionate 
and SCFAs in the bloodstream of rats induce ASD with biochemical changes associated to 
increased oxidative stress, altered lipid profiles, innate neuroinflammatory response and 
mitochondrial dysfunction (Macfabe, 2012).  
All considered, it is possible that the increase in intestinal permeability (Shukla et al., 2015; 
Giloteaux et al., 2016), together with the increase in SCFAs, could promote the massive transfer 
of SCFAs, especially acetate and propionate, into the bloodstream, causing increased oxidative 
stress and mitochondrial dysfunction in CFS/ME.  
We found high levels of several indole derivatives only in CFS/ME patients. Indole is a 
metabolite mainly produced in the gut from tryptophan by microbiota activity using 
tryptophanase, an enzyme able to hydrolyze tryptophan to obtain indole, pyruvate, and 
ammonia (Lee and Lee, 2010). It has been demonstrated that indole and other metabolites 
derived from tryptophan can modulate inflammation in the gastrointestinal tract (Bansal et al., 
2010; Nicholson et al., 2012) and support epithelial tight junction permeability (Keszthelyi et 
al., 2012). Indole is absorbed at the level of the intestinal mucosa and through the entero-hepatic 
circulation reaches the liver where it is transformed into indican to be then excreted with urine. 
High levels of indican in the urine are a symptom of dysbiosis in the small intestine, and is 
associated to altered fermentative or putrefactive processes (Macfarlane and Macfarlane, 1997). 
Several bacterial species have been shown to produce large amount of indole, including both 
Gram-positive and Gram-negative bacteria. Among the latter, E. coli and Bacteroides sp. are 
able to hydrolyze tryptophan to obtain indole (Lee and Lee, 2010). The high levels of indole 
derivatives found in our work could be related to the increase in the abundance of the genus E. 
coli/Shigella and Bacteroides sp. observed in fecal samples from CFS/ME patients.  
In subjects with CFS/ME, we also observed an increase, although not statistically significant, 
in biogenic amines, particularly dopamine, 3-Methoxytyramine and N-Acetylputrescine. 
Dopamine is the most common catecholamine in the CNS. Within the brain, dopamine acts as 
a neurotransmitter, through the activation of specific receptors, and plays several important 




neurotransmitters, including dopamine (Clarke et al., 2014). Dopamine is not able to cross the 
blood–brain barrier, so its synthesis and functions in peripheral areas are independent of those 
in the brain. A substantial amount of dopamine is released in the bloodstream performing an 
exocrine or paracrine function in various peripheral systems, including the immune system, 
reducing the activation level of lymphocytes (Sarkar et al., 2010).  
Consequently, changes in dopamine levels may be associated in some way to the 
























Overall, CFS/ME patients showed alterations in the composition of both the fecal and salivary 
microbiota, with more marked differences observed in the gut. While confirming the results of 
previous studies (Fremont et al., 2012; Shukla et al., 2015; Giloteaux et al., 2016), our data add 
new information and support the autoimmune hypothesis for CFS condition (Patarca, 2001; 
Skowera et al., 2002; Fluge et al., 2011; Sotzny et al., 2018) in that the intestinal microbial 
profile we recorded in CFS/ME patients is consistent with that reported for autoimmune 
conditions, such as Chron’s disease (Manichanh et al., 2006), ulcerative colitis (Maukonen et 
al., 2015) and Systemic Lupus Erythematous (Hevia et al., 2014). 
In CFS/ME patients, the decrease in the abundance of several butyrate-producing bacteria 
belonging to Lachnospiraceae may result in the alteration of the integrity of the intestinal 
barrier and in a reduced protective action against gut inflammation. The increase of Bacteriodes 
species, some of which are able to damage the intestinal barrier by means of their virulence 
factors, may compromise the permeability of the intestinal barrier, resulting in a “leaky gut”, 
and promote bacterial translocation in the bloodstream, causing an abnormal systemic 
inflammatory response.  
As oral microbial communities are closely connected with the intestinal microbiota and 
influence its composition, the higher prevalence in CFS/ME patients of oral opportunistic 
pathogens (i.e. Rothia dentocariosa) able to cause infections in several body sites, may alter the 
composition of their gut microbiota and dysregulate their immune tolerance. 
The gradual increase or decrease of most bacterial taxa observed in CFS/ME patients and in 
their relatives compared to external controls, suggest the presence of a modified microbiome 
profile also in patients’ relatives, affected by genetic and environmental factors (i.e. diet and/or 
environmental pollution). 
The metabolic analysis carried out on a sub-sample of the three experimental populations 
allowed to record some differences in the fecal metabolic profiles of CFS/ME patients. 
Although the observed differences were not statistically significant, some data appear very 
interesting and deserve to be deeper investigated. These results, if confirmed by using a larger 
cohort, may lead to a better understanding of the relationship between metabolic changes and 
CFS/ME-related immunological and cognitive dysfunctions.  
It is worth emphasizing that the use of different patient inclusion/exclusion criteria and inter-




difficult to compare our results to the outcomes of previous studies. Furthermore, we also have 
to take into account that the presence of CFS/ME subgroups and heterogeneity in symptoms 
often hinder the accurate diagnosis of the disease.  
The use of NGS techniques allowed us to obtain many information on the intestinal and oral 
microbiota composition of CFS/ME patients in a relatively short time. Few recorded differences 
showed statistical significance. This is likely due to both sample size and heterogeneity of the 
syndrome. In Italy, the lack of epidemiological studies and doctors able to recognize and 
diagnose the syndrome correctly makes it difficult to recruit a sufficiently large cohort of 
subjects. 
Despite these difficulties, this work represents the first microbiological study carried out on an 
Italian population of CFS/ME by applying the NGS techniques and including the relatives of 
CFS/ME patients. The collaboration of the Italian Association of CFS patients - AMCFS Onlus, 
which relies on a team of experienced doctors and is committed to the development of CFS/ME 
guidelines, was very helpful for getting in touch with patient and their relatives.  
In conclusion, to obtain data that are truly representative of the pathological condition it will be 
of crucial importance to analyze a larger cohort of patients and perform longitudinal studies 
using the same workflow. 
Further studies are needed to better understand whether the alteration of the microbiota is a 
cause or a consequence of the onset of CFS/ME and if the alterations of the microbiota are 
related to any of the several secondary symptoms. Despite evidences of altered composition of 
the intestinal and oral microbiota in CFS/ME, a specific microbial signature attesting a 
pathogenic role of the microbiota in CFS/ME has not yet been identified. If our results will be 
confirmed by larger studies, the differences detected in the microbial and metabolic profiles of 
CFS/ME patients may be used as markers for a more accurate diagnosis of the syndrome and 
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